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ABSTRACT 
Opioid abuse has become a global epidemic and is now a huge public health concern here in the 
US. Non-medicinal use of opioid prescription drugs is at the forefront of the epidemic and 
considered the “gateway” drug to other illicit opioid use. As opioid prescribing has increased 
over the last decade in the US, so has opioid-related deaths, surpassing car accidents and suicide 
as the leading cause of injury-related deaths. Medication assisted treatment (MAT) is 
fundamental in decreasing opioid abuse overdose and mortality. Therefore, the research study 
aims to determine if counseling adherence, opioid abstinence, and retention in MATs are 
influenced by personal characteristics, socio-economic factors, readiness to change, social 
support, and integrated care. Guided by social cognitive theory, transtheoretical model, and 
theory of reasoned action, the study will employ a retrospective cohort design utilizing opioid 
dependent patients from a MAT Program in West Florida. Analysis of three cox regression 
models indicated for personal factors: an increase in age was associated with patients being more 
likely to adhere to counseling (p=.001) and retention (p=.034), full-time employment (p=.043) 
was positively associated with opioid abstinence, whereas part-time employment (p=.037) was 
positively associated with retention, having insurance (public: p=.000) was positively associated 
with counseling adherence, opioid abstinence (public: p=.000, private: p=.035) and retention 
(public: p=.000, private: p=.000). With regards to environmental influences, social support was 
positively associated with opioid abstinence (p=.022) and integrated care was positively 
associated with opioid abstinence (p=.027) and retention (p=.000). Examining these factors are 
necessary to improve treatment adherence and expand MAT programs. Additionally, providing 
funding is crucial for practitioners to continually create educational intervention strategies to 
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engage patients in treatment, thereby reducing the opioid overdose epidemic. This study extends 
the literature contributing to understanding personal factors and environmental influences in 
MATs. 
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I dedicate this research study to my parents, Delores and Vincent Placide. I will never be 
able to thank you enough for your countless sacrifices and support through the years. Thank you 
for your unconditional love and prayers and instilling in me at an early age the importance of 
faith and family. 
 vi 
ACKNOWLEDGMENTS 
“Trust in the Lord with all your heart and lean not on your own understanding; in all your 
ways acknowledge Him, and He shall direct your paths.” Proverbs 3:5-6 Thank you Lord for 
your wisdom, guidance and grace. For providing hope and peace in moments of despair, as well 
as patience to fulfill your purpose for my life. 
I am especially grateful to my dissertation chair, Dr. Lynn Unruh, who has been an 
exceptional adviser throughout my studies. Thank you for your guidance, support, and expecting 
nothing but the best from your students. Thank you for challenging me. Although you were on 
sabbatical for a year, you still continuously dedicated your time and knowledge to see this 
dissertation to completion. To my dissertation committee members, Dr. Danielle Atkins, Dr. 
Latarsha Chisholm, and Dr. J. Blake Scott, thank you for your professional and personal 
guidance. I am thankful to my chair and each committee member for your willingness to serve 
on my committee and your thoroughness in creating a quality product.  
I am appreciative for the financial support from The College of Graduate Studies, The 
Doctoral Program of Public Affairs, Health Management and Informatics Department, Student 
Government Association, and the Eagle Advancement Institute. Thank you for your commitment 
to graduate students’ abilities to achieve academic excellence.  
Thank you to the Doctoral Program of Public Affairs’ faculty and staff for their continued 
support. Dr. Robyne Stevenson, thank you for stepping in as interim director during my cohort’s 
initial year and for the first conference presentation opportunity as a doctoral student. To Dr. 
Stephen Holmes and Dr. Jacinta Gau, thank you for providing me with a solid foundation in 
Statistics. Denise and Jesica, thank you for always supporting the administrative needs of the 
 vii 
PAF students. I am also appreciative to my cohort, from the countless study sessions, to the 
encouraging words shared to motivate me in pushing forward. Amanda, Atalie, Carla, and 
Michelle, thank you for your support through this process. In addition, I would also like to thank 
the faculty and staff in the Health Management and Informatics Department. A special thank you 
to Dr. Kourtney Nieves for providing me with the opportunity to teach undergraduate courses, 
and being a wonderful supervisor, and Terry for your wit and listening ear. To Chantel, Ms. 
Sandi and the Office of Student Involvement staff and students, thank you for assisting me in 
balancing my academics with student involvement, and introducing me to the additional 
resources at UCF outside of academia.  
I am extremely grateful to the Behavioral health agency who provided me with secondary 
data to complete this study. Thank you for being advocates for a population often stigmatized 
and providing patient-centered care for those in need of treatment. 
And most importantly, to my family. I am truly blessed to have a family who has 
continuously prayed, encouraged and supported me. I would like to thank my parents for their 
unconditional love and sacrifices. To my sisters, Veda, Vickki, and Sheron, and their families, 
for your inspiration, motivation, and guidance. To my nephews, Makai, Tyler and Brandon, 
know that you will always have the love and support of family, and with faith anything is 
possible. To my extended family -especially my uncles, aunts and cousins- and friends, thank 
you for your prayers and for every phone call and text filled with encouraging words. To my dear 
friends Gabby, Natalie and Sabria, thank you for your laughter, patience, and encouragement. As 
I continue on this journey of life, I sincerely thank the collective efforts of everyone for their 
prayers, love, guidance, and support in attaining this educational achievement. 
 viii 
TABLE OF CONTENTS 
ABSTRACT ................................................................................................................................... iii 
ACKNOWLEDGMENTS ............................................................................................................. vi 
TABLE OF CONTENTS ............................................................................................................. viii 
LIST OF FIGURES ....................................................................................................................... xi 
LIST OF TABLES ........................................................................................................................ xii 
LIST OF ACRONYMS ............................................................................................................... xiii 
CHAPTER ONE: INTRODUCTION ............................................................................................. 1 
Background ............................................................................................................................... 1 
Purpose of the Study ................................................................................................................. 3 
Significance of the Study .......................................................................................................... 3 
Definition of Terms................................................................................................................... 7 
CHAPTER TWO: LITERATURE REVIEW ................................................................................. 8 
Opioid Prescription Drug Abuse ............................................................................................... 8 
Opioid Dependence ................................................................................................................... 9 
Medication Assisted Treatment (MAT) .................................................................................. 10 
Methadone. ........................................................................................................................... 11 
Buprenorphine. ..................................................................................................................... 12 
Naltrexone. ........................................................................................................................... 13 
Indicators of Successful Medication Assisted Treatment Outcomes ...................................... 13 
Counseling Adherence. ........................................................................................................ 14 
Opioid Abstinence. ............................................................................................................... 14 
Retention. ............................................................................................................................. 14 
Possible Factors Associated with Treatment Outcomes ......................................................... 15 
Personal Characteristics ....................................................................................................... 16 
Socio-economic Factors ....................................................................................................... 17 
Readiness to Change. ........................................................................................................... 18 
Support Systems. .................................................................................................................. 19 
Integrated Care. .................................................................................................................... 20 
Summary of Possible Factors Associated with Treatment Outcomes.................................. 21 
Theoretical Framework ........................................................................................................... 21 
Social Cognitive Theory....................................................................................................... 21 
 ix 
Transtheoretical Model. ....................................................................................................... 22 
Theory of Reasoned Action.................................................................................................. 23 
Applications of the Theoretical Approach in Studies. ......................................................... 24 
Conceptual Framework ........................................................................................................... 27 
CHAPTER THREE: METHODOLOGY ..................................................................................... 30 
Research Questions & Hypotheses ......................................................................................... 30 
Research Design...................................................................................................................... 34 
Population & Sample .............................................................................................................. 34 
Setting................................................................................................................................... 35 
Ethics. ................................................................................................................................... 36 
Study Variables/ Measures ..................................................................................................... 37 
Dependent Variables. ........................................................................................................... 37 
Independent Variables. ......................................................................................................... 38 
Controls. ............................................................................................................................... 40 
Data Collection ....................................................................................................................... 42 
Data Analysis .......................................................................................................................... 43 
Survival Analysis. ................................................................................................................ 44 
Power Analysis. .................................................................................................................... 46 
CHAPTER FOUR: RESULTS ..................................................................................................... 48 
Descriptive Analysis ............................................................................................................... 48 
Bivariate Analysis ................................................................................................................... 51 
Correlation. ........................................................................................................................... 51 
ANOVA. .............................................................................................................................. 52 
Survival Analysis .................................................................................................................... 59 
Kaplan Meier Method. ......................................................................................................... 59 
Multicollinearity Assumption. ............................................................................................. 71 
Cox Regression Analysis. .................................................................................................... 72 
Conclusions of Hypothesis Testing ........................................................................................ 83 
Personal Factors. .................................................................................................................. 83 
Environmental Influences. ................................................................................................... 89 
CHAPTER FIVE: DISCUSSION ................................................................................................. 92 
Discussion of Findings ............................................................................................................ 92 
Personal Factors. .................................................................................................................. 92 
 x 
Environmental Influences. ................................................................................................... 94 
Controls. ............................................................................................................................... 95 
Limitations .............................................................................................................................. 96 
Strengths & Generalizability ................................................................................................... 97 
Implications............................................................................................................................. 99 
Policy Implications. .............................................................................................................. 99 
Program Implications. ........................................................................................................ 101 
Future Research .................................................................................................................... 103 
Conclusion ............................................................................................................................ 104 
APPENDIX A: PRIOR MEDICATION ASSISTED TREATMENT STUDIES ...................... 106 
APPENDIX B: THEORETICAL APPROACHES LITERATURE REVIEW SUMMARY..... 112 
APPENDIX C: LETTER OF SUPPORT ................................................................................... 119 
APPENDIX D: INSTITUITONAL REVIEW BOARD APPROVAL ....................................... 121 
APPENDIX E: MEDICAL EXAMINERS COMMISSION DRUG REPORT USAGE 
APPROVAL ............................................................................................................................... 125 
REFERENCES ........................................................................................................................... 128 
 
 xi 
LIST OF FIGURES 
Figure 1. Historical overview of hydrocodone, oxycodone, and methadone deaths. ..................... 4 
Figure 2. Historical overview of fentanyl deaths. ........................................................................... 5 
Figure 3. Historical overview of cocaine deaths. ............................................................................ 5 
Figure 4. Historical overview of heroin deaths. .............................................................................. 6 
Figure 5. Conceptual Framework. ................................................................................................ 28 
Figure 6. Insurance and Counseling Adherence. .......................................................................... 63 
Figure 7. Insurance and Opioid Abstinence. ................................................................................. 63 
Figure 8. Insurance and Retention. ............................................................................................... 64 
 Figure 9. Social Support and Opioid Abstinence......................................................................... 65 
Figure 10. Social Support and Retention. ..................................................................................... 65 
Figure 11. Integrated Care and Counseling Adherence. ............................................................... 66 
Figure 12. Integrated Care and Opioid Abstinence. ..................................................................... 67 
Figure 13. Integrated Care and Retention. .................................................................................... 67 
Figure 14. Primary Drug Dependence and Opioid Abstinence. ................................................... 68 
Figure 15. Criminal History and Retention................................................................................... 69 
Figure 16. Medication Prescribed and Counseling Adherence. .................................................... 70 
Figure 17. Medication Prescribed and Opioid Abstinence. .......................................................... 70 
Figure 18. Medication Prescribed and Retention. ......................................................................... 71 
Figure 19. Counseling Adherence survival curve. ........................................................................ 76 
Figure 20. Opioid Abstinence Survival Curve. ............................................................................. 79 
Figure 21. Retention Survival Curve. ........................................................................................... 83 
  
 xii 
LIST OF TABLES 
Table 1 Operational Definitions of the Study Variables ............................................................... 41 
Table 2. Sample Characteristics .................................................................................................... 49 
Table 3. Correlations between counseling adherence and continuous independent variables ..... 51 
Table 4. Correlations between opioid abstinence and continuous independent variables ............ 51 
Table 5. Correlations between retention and continuous independent variables .......................... 51 
Table 6. ANOVA of Counseling Adherence and the categorical independent variables ............. 53 
Table 7. ANOVA Analysis of Opioid Abstinence and categorical independent variables .......... 55 
Table 8. ANOVA Analysis of Retention in treatment and categorical independent variables ..... 58 
Table 9. Kaplan Meier table of covariates and treatment outcomes. ............................................ 60 
Table 10. Cox regression predicting number of weeks adhering to counseling in treatment ....... 74 
Table 11. Cox regression, predicting number of days abstaining from opioids ........................... 78 
Table 12. Cox regression, predicting number of days retained in treatment. ............................... 81 
Table 13. Hypothesis Testing Summary ....................................................................................... 90 
Table 14. Prior Medication Assisted Treatment Studies ............................................................ 107 
Table 15. Theoretical Approaches Literature Review Summary................................................ 113 
 
 xiii 
LIST OF ACRONYMS 
ANOVA – Analysis of variance 
ASAM – American Society of Addiction Medicine  
CAST – Community Access to Specialized Treatment 
CDC – Centers for Disease Control and Prevention 
CFR – Code of Federal Regulations 
DEA – Drug Enforcement Agency 
DSM - Diagnostic and Statistical Manual of Mental Disorders 
EHR – Electronic Health Record 
GED – General Equivalency Diploma 
HCV – Hepatitis C Virus 
HHS – United States Department of Health and Human Services 
HIPAA – Health Insurance Portability and Accountability Act 
HIV – Human Immunodeficiency Virus 
HR – Hazard Ratio 
IRB – Institutional Review Board 
MAT – Medication Assisted Treatment 
NIDA – National Institute on Drug Abuse 
PDMP – Prescription Drug Monitoring Program 
PHI – Protected Health Information 
SA – Survival Analysis 
SAMHSA – Substance Abuse and Mental Health Services Administration 
 xiv 
SCT – Social Cognitive Theory 
SES – Socio-economic status 
TTM – Transtheoretical Model 
UDS – Urine drug screen 
URICA – University of Rhode Island Change Assessment 
VIF – Variance Inflation Factors 
 1 
CHAPTER ONE: INTRODUCTION 
Within the last decade, opioid abuse has become a major public health concern. The 
prescription drug abuse epidemic has caused a substantial burden on society, including disease 
transmissions as a result of injection drug use [Human Immunodeficiency Virus (HIV) and 
Hepatitis C (HCV)], work productivity loss, and crime (Franckowiak & Glick, 2015; Banta-
Green, Maynard, Koepsell, Wells, & Donovan, 2009; Hubbard, Craddock & Anderson, 2003). 
The Centers for Disease Control and Prevention (CDC) has compared the current opioid 
epidemic in the US to the HIV epidemic of the late 1980s and early 1990s (CDC, 2016a; Park & 
Bloch, 2016, para 5; American Society of Addiction Medicine, n.d.). Overdose deaths as a result 
of opioid drugs have surpassed car accidents as the leading cause of injury-related deaths in the 
US (Hwang, Turner, Kruszewski, Kolodny & Alexander, 2016; CDC, 2011, Paulozzi, 2012).  
Background 
An estimated 2.2 million people in the US abuse opioids, of which 1.8 million are opioid 
dependent (Substance Abuse and Mental Health Services Administration [SAMHSA], 2015; 
Rusch, 2016). Non-medicinal opioid prescription drugs are considered a “gateway drug” and 
have been at the forefront of the opioid epidemic (National Institute on Drug Abuse [NIDA], 
2014; Maxwell, 2015; Zullig, Divin, Weiler, Haddox & Pealer, 2015). The increase in opioid 
prescribing is associated with a surge in opioid diversion (medical prescriptions diverted to 
others for recreational, non-medicinal purposes), opioid abuse, and unintentional overdose deaths 
(Alford, 2016; Zosel, Bartelson, Bailey, Lowenstein, & Dart, 2013; Dowell, Haegerich, & Chou, 
2016; Hwang et al., 2016; Turk, Dansie, Wilson, Moskovitz & Kim, 2014; Kresina & Lubran, 
2011; Rusch, 2016). 
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The state of Florida in particular, was sluggish to enact opioid prescribing restriction 
laws, which resulted in an upsurge in opioid prescribing. In 2010, 98 of the top 100 oxycodone-
prescribing physicians practiced in the state of Florida (Tozzie, 2014). Hence there was a 
combined effort to decrease the crisis. Within the next two years this declined due to the 
Prescription Drug Monitoring Program (PDMP) legislation signed in 2009 with mandatory 
reporting requirements stating in 2011, The Drug Enforcement Agency Initiatives (Operation 
Oxy Ally and Operation Pill Nation), and the Pill Mill Law, whose restrictions closed the illegal 
practices of “pill mills” (Kennedy-Hendricks et al., 2016; Florida Senate, 2011). The rates have 
therefore increased of those who sought another drug (heroin for instance) or effective treatment 
through medication assisted treatment (MAT) programs to deal with withdrawals (Connery, 
2015; Matson, Hobson, Abdel-Rasoul, & Bonny, 2014; Banta-Green et al., 2009; Timko, 
Schultz, Cucciare, Vittorio & Garrison-Diehn, 2016). 
SAMHSA (2015) notes the increase in the proportions of patients admitted nationally to 
drug rehabilitation programs for opioid dependence -four percent for heroin and six percent for 
non-medicinal prescription increase- due to the epidemic. The US Department of Health and 
Human Services (HHS) has therefore made MAT a priority. In 2015, HHS discussed its 
intentions to address treatment needs of those suffering with opioid dependence, and in 2016 the 
US President’s budget included funding specifically for the expansion of using medication-
assisted treatment to facilitate treatment for a large proportion of the population with opioid 
dependence (Rusch, 2016).  
MAT is a critical component to decreasing opioid abuse overdose and mortality (Dennis 
et al., 2015; Rusch, 2016; Stotts, Dodrill, & Kosten, 2009; Jones, Campopiano, Baldwin, & 
McCance-Katz, 2015; Kresina & Lubran, 2011). MAT is a chronic treatment approach for opioid 
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dependence similar to treatment of diseases such as diabetes and hypertension (HHS, 2011; 
Stotts et al., 2009). The monitored medication helps addicted individuals achieve a normal state 
of mind (reducing cravings and withdrawals) and allows individuals to be productive citizens 
(HHS, 2011, p. 5; Jones et al., 2015). MAT is a combination of medication and counseling 
tailored to each person’s treatment needs, therefore maintenance and stabilization is 
individualized and differs for each patient (HHS, 2011; Stotts et al., 2009).  
Purpose of the Study 
With the increase in opioid dependent individuals fueled by the prescription drug abuse 
crisis, individuals successfully progressing through treatment are a vital component in reducing 
the epidemic. Therefore, the research study aims to determine if counseling adherence, opioid 
abstinence, and retention in MATs are influenced by: 
1. Personal characteristics – gender, race, age, relationship status 
2. Factors which contribute beyond personal characteristics, specifically socio-economic 
factors – education, employment, income, health insurance 
3. Readiness to change 
4. Having a support system – social support 
5. Receiving integrated care 
The study will integrate the social cognitive theory, transtheoretical model, and theory of 
reasoned action in order to assess these factors.  
Significance of the Study 
Drug-overdose deaths in the US have almost tripled within the last two decades, with 
opioid-related deaths accounting for 60.9% (Rudd, Seth, David & Scholl, 2016). Florida is one 
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of 19 states, which saw a statistically significant increase in drug overdose deaths between 2014 
and 2015 (CDC, 2016b). Figures 1 – 4, illustrate the changes in drug-related deaths (if the drug 
was the cause of death and present in the body at time of death) involving several types of 
opioids, cocaine, and heroin in Florida, as indicated by the Medical Examiners Report (Florida 
Department of Law Enforcement [FDLE], 2016). Figure 1 shows there was an increase in deaths 
of three opioids until 2010, at which time deaths decreased and remained at a lower level for a 
few years, then increased within the last year. The decrease in deaths correspond with the 
combined legislative and law enforcement efforts -enactment of the Florida Pill Mill Law, DEA 
Initiatives (Operation Oxy Ally and Operation Pill Nation)-, and later implementation of the 
PDMP. Fentanyl (shown in figure 2) and heroin (shown in figure 4) have rapidly increased in the 
last two years while cocaine (figure 3) has fluctuated in prior years and is on the rise again. 
 
 
Figure 1. Historical overview of hydrocodone, oxycodone, and methadone deaths. This figure 
illustrates the changes in Florida deaths inclusive of if the drug was the cause of death or 
present in the body at time of death (FDLE, 2016).  
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Figure 2. Historical overview of fentanyl deaths. This figure illustrates the changes in Florida 
fentanyl deaths inclusive of if the drug was the cause of death or present in the body at time of 
death (FDLE, 2016). 
 
    
Figure 3. Historical overview of cocaine deaths. This figure illustrates the changes in Florida 
cocaine deaths inclusive of if the drug was the cause of death or present in the body at time of 
death (FDLE, 2016). 
 6 
 
Figure 4. Historical overview of heroin deaths. This figure illustrates the changes in Florida 
heroin deaths inclusive of if the drug was the cause of death or present in the body at time of 
death (FDLE, 2016).  
 
With the current opioid abuse climate, determining effective treatment modalities are 
essential. MAT is a prevention strategy to decrease opioid overdose deaths if patients are 
engaged in treatment. High relapse and lack of retention in treatment has plagued those with an 
opioid dependence. Considering the increase over the years in opioid prescription drug abuse, 
and the consequential effects created, it is important to understand the personal characteristics 
and socio-economic factors related to retention in treatment as well as the effects of readiness to 
change, support systems and integrated care on counseling adherence, abstaining from opioids, 
and retention in treatment. The study contributes to extending the literature on MAT and has 
implications to support educational, regulatory, clinical and multidisciplinary intervention 
strategies to combat the epidemic. The study provides a better understanding of factors that are 
associated with treatment outcomes.  
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Definition of Terms 
Counseling adherence (CA): patients complying with the counseling sessions/visits agreed on 
in the initial treatment plan 
Medication-assisted treatment (MAT): addiction treatment with medication and counseling for 
opioid dependent individuals. 
Opioids: drugs that interact with opioid receptors on nerve cells in the brain and body (often 
prescribed to treat pain). 
Opioid abstinence (OA): abstaining from all opioids during treatment with the exception of the 
medication – methadone, buprenorphine. 
Opioid dependence: the effects of opioid misuse results in changes to the brain that causes 
addiction, and dependency on the drug. 
Prescription drug abuse: the intentional use of psychoactive medications without a physician’s 
prescription or in a way not advised by the prescribing doctor. 
Retention (R): the length of time patients are engaged in medication treatment after admission 
Socio-economic factors: social and economic measure of an individual’s status in comparison to 
others based on education, employment, income and health insurance 
Social support: being a part of a supportive social network i.e. friends, relatives  
Stages of Change: assesses individuals’ readiness to change towards a healthier behavior 
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CHAPTER TWO: LITERATURE REVIEW 
The literature review section illustrates the magnitude of the research problem and 
provides a frame of reference on opioid dependence and medication-assisted treatment. Relevant 
literature on prescription opioid drug abuse, opioid dependence, MAT, indicators of successful 
treatment outcomes, and possible factors related to treatment outcomes - personal characteristics, 
socio-economic factors, readiness to change, social support and integrated care- are discussed. 
The chapter concludes with the theoretical approaches: social cognitive theory transtheoretical 
model, and theory of reasoned action, guiding the study.  
Opioid Prescription Drug Abuse 
Substance use remains an urgent public health problem, due to its physical, mental, social 
and financial ramifications. Over $600 billion is lost annually in the US as a consequence of 
substance use due to health care, crime, and work loss productivity (National Drug Intelligence 
Center, 2010; NIDA, 2011; Franckowiak & Glick, 2015). In particular, opioid prescription drug 
abuse has become a significant public health concern over the last decade, because of its 
association with medical complications requiring emergency department visits, increased risks of 
overdose, and mortality (Nargiso, Ballard & Skeer, 2015; Compton & Volkow, 2006; NIDA, 
2014; Drazdowski, 2016; Phillips, 2013). Opioid prescription use for the treatment of pain has 
increased over the last two decades primarily due to the aggressive marketing of pain 
management (Zee, 2009; Phillips, 2013). The CDC has noted that the steady increase in opioid 
prescribing shows a parallel increase in opioid addiction and overdose deaths (2016b). 
Prescription drugs are comprised of the same drug categories as illicit drugs, therefore 
similar pharmacological factors associated with addiction and abuse also apply to prescription 
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drugs (Compton & Volkow, 2006). For instance, oxycodone, oxycontin, and hydrocodone are 
opioids, the same category as heroin; whereas amphetamines and methylphenidate are 
stimulants, like methamphetamine and cocaine (Compton & Volkow, 2006; Jones, Fullwood & 
Hawthorne, 2012). 
The CDC (2016b) indicates that over the last 2 decades the increase in opioid 
prescriptions alone has resulted in an opioid overdose epidemic with approximately 115 deaths 
per day. Of the 20% of the US population 12 years and older abusing prescription medications, 
opioids, are one of the most misused (SAMHSA, 2013a; Fleary, Heffer & McKyer, 2011; 
Phillips, 2013). Nearly 2 million Americans aged 12 or older were either dependent on or abused 
prescription opioids in 2014 (CDC, 2016b). Many patients are prescribed doses that increase the 
probability of becoming addicted to opioids (Caccavale, 2016).   
Opioid Dependence 
 Pharmacological dependence, impaired control, risky use and social impairment are the 
categories from which the DSM-V (Diagnostic and Statistical Manual of Mental Disorders) uses 
to define at least two of the eleven criteria for the presence of a substance use disorder (Rusch, 
2016).  Opioid dependence is defined as “a chronic brain-based disorder with a high potential for 
relapse” (Timko et al., 2016, p. 22). The complexity of opioid dependence has caused a 
significant strain on the health care system (increased health care utilization, increased blood 
borne viruses – HIV, HCV), criminal justice system, and family life to name a few (Stotts et al., 
2009; Timko et al., 2016). Those exposed to opioids follow a general path. Whether drugs are 
obtained through diversion (for recreational use) or a prescription, tolerance evolves leading to 
misuse (Rusch, 2016). Swallowing non-medicinal prescription drugs advance to chewing, then 
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crushing, snorting and/or intravenous drug use, to release the drug more rapidly as the 
dependence develops (Rusch, 2016, p. 8; Kresina & Lubran, 2011). Vulnerability to opioid 
dependence is behaviorally complex, encompassing environmental, psychological, and 
biological influences (Kresina & Lubran, 2011, p. 4103). 
Annual treatment admissions for patients addicted to opioids have almost doubled within 
the last decade in the US; with opioids only second to alcohol as the primary reason for 
admission to addiction treatment (Timko et al., 2016; SAMHSA, 2015; Banta-Green et al., 2009; 
Franckowiak, & Glick, 2015; Jones et al., 2015). In some states, admissions have increased 10-
fold, which is parallel to the increase in prescription opioid abuse (Banta-Green et al., 2009). 
Opioid treatment (MAT) in communities are often limited, as abstinence is still seen as the 
preferred method in many sectors – public, justice and legal system, mental health following the 
Alcoholic Anonymous (AA) 12-step program, which is inadequate for opioid dependent 
individuals (Rusch, 2016). For the last few decades, treatment programs have shifted from 
abstinence to harm-reduction treatment supporting pharmacotherapy for opioid dependents 
(Smyth et al., 2005).  
Medication Assisted Treatment (MAT) 
MAT is “the use of pharmacotherapies in combination with counseling and behavior 
therapies to provide a comprehensive therapeutic approach to the treatment of opioid abuse and 
dependence” (Kresina, & Lubran, 2011, p. 4104).  MAT previously referred to as methadone 
maintenance treatment was developed to reduce drug cravings and withdrawal symptoms 
(sweats, chills, joint pain, vomiting, and diarrhea) and ultimately prevent relapse for opioid 
dependent individuals (Rusch, 2016; Darker, Ho, Kelly, Whiston, & Barry, 2016; Jones et al., 
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2015). Appendix A provides a table summary of prior MAT studies. MAT is recognized as an 
effective treatment choice for opioid dependence (Saxon, Hser, Woody, & Ling, 2013; Vogel, 
Dürsteler, Walter, Herdener, & Nordt, 2017; Wasserman, Stewart & Delucchi, 2001; Darker et 
al., 2016; Franckowiak & Glick, 2015; Jones et al., 2015). However, only an approximate eight 
percent of those suffering from opioid dependence receive MAT (Vogel et al., 2017). The World 
Health Organization (WHO) (2009) has advocated for long-term strategy care (open-ended 
treatment, a lifetime of treatment if necessary) of MAT for this population. The Food and Drug 
Administration (FDA) has approved three medications – methadone, buprenorphine, and 
naltrexone for the treatment of opioid dependence (Timko et al., 2016). 
Methadone. 
The effectiveness of methadone maintenance treatment has been well established for 
heroin addiction for decades (Cushman, Trussell, Gollance, Newman & Bihari, 1976; Dole & 
Nyswander, 1976; Dole & Joseph, 1978; Kresina & Lubran, 2011; Kreek, Borg & Ray, 2010; 
Banta-Green et al., 2009; Saxon et al., 2013; Jones et al., 2015). Due to the opioid epidemic 
fueled by prescription drugs, an increasing number of opioid dependents who used non-
medicinal prescription drugs or poly users are seeking MAT. Due to cost, methadone is usually 
the most utilized medication. Methadone is a synthetic opioid shown to reduce morbidity and 
mortality in opioid dependents (research studies usually reference heroin-use addicts) (HHS, 
2011; Timko et al., 2016; Darker et al., 2016). Methadone was previously dispensed in 
“methadone maintenance clinics,” however many clinics now also dispense buprenorphine, and 
have recently started naltrexone. After ingesting orally, methadone absorbs rapidly with initial 
effects experienced within 30 minutes (Saxon et al., 2013; Darker et al., 2016). The complexity 
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of methadone metabolism is evident in the enzymes ability to exhibit individual variation based 
on environmental factors and genetics (Saxon et al., 2013, p. S70; Darker et al., 2016). The 
average dose rages from 80 – 100 mg, however some patients stabilize at a lower or higher dose 
(Saxon et al., 2013). Methadone is a full µ-opioid receptor agonist, while buprenorphine is only a 
partial agonist (Saxon et al., 2013; Timko et al., 2016, p. 23). Feeling normal, with cravings 
under control, minor or no side effects and no withdrawals, are indicators that individuals have 
reached their stabilization dose (HHS, 2011). Withdrawal symptoms include: nausea, vomiting, 
excessive sweating, diarrhea, anxiety and sleep issues (HHS, 2011). Side effects from methadone 
include: drowsiness, respiratory problems, and constipation (Darker et al., 2016). Methadone can 
be initiated at the start of recovery, unlike buprenorphine (once withdrawal has started), and 
naltrexone (7 – 10 days after withdrawal, to ensure no opioids in the patient’s system) (HHS, 
2011). 
Buprenorphine. 
The FDA approved Buprenorphine in 2002 for the treatment of opioid dependence. It is 
used both in opioid detoxification and maintenance treatment (Timko et al., 2016). 
Buprenorphine is usually referred to by its drug name of suboxone or subutex (generic drug). 
The route of administration is sublingual through tablet or film in three formulations (Timko et 
al., 2016; Saxon et al., 2013). Two of the sublingual formulations (tablet and film) are combined 
with naloxone to prevent medication misuse via injection (Saxon et al., 2013). Withdrawals and 
physical dependence is less severe with buprenorphine as a partial agonist versus methadone 
(full agonist) (Timko et al., 2016, p. 23). “It has a ceiling effect on µ-opioid receptor” which 
does not increase effects after ingesting a dose, decreasing the possibility of an overdose and 
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depression (Saxon et al., 2013, p. S70). One of the benefits of buprenorphine is the ability to 
receive a prescription outside of a maintenance treatment program (the sample for this study will 
only include patients in a maintenance treatment program). A disadvantage is the cost; therefore, 
it is less available to those without adequate resources (Timko et al., 2016). 
Naltrexone. 
Naltrexone is the only non-opioid treatment. It blocks all effects of opioids and does not 
produce euphoric effects (Timko et al., 2016; Kresina & Lubran, 2011; Pecoraro, Ma & Woody, 
2012). Unlike methadone and buprenorphine which activates opioid receptors to negate cravings, 
naltrexone binds and blocks the receptors (SAMHSA, 2016, para. 2). It can be administered in an 
extended release form -via injection once per month, intramuscularly- or orally in tablet form 
(Timko et al., 2016). Starting treatment requires initial withdrawal from opioid substances for a 
minimum of seven to ten days of detoxification prior, otherwise extra strong withdrawal effects 
will be experienced (Kresina & Lubran, 2011; Stotts et al., 2009; SAMHSA, 2012). Naltrexone 
does not require a taper or cause withdrawal symptoms if someone is stable in recovery and 
wants to stop the medication (which should include physician consultation) (SAMHSA, 2012). 
Indicators of Successful Medication Assisted Treatment Outcomes 
 MAT has showed improved ability for opioid dependents to function as respectable 
citizens. Similar to diabetic or hypertension patients receiving medications for their illnesses, this 
form of treatment for opioid addicts works. Counseling adherence, opioid abstinence and 
retention in treatment are behaviors that have indicated decreases in drug use and mortality, 
while improving the quality of life (Timko et al., 2016; Kelly, O’Grady, Mitchell, Brown & 
Schwartz, 2011; Saxon et al., 2013; Banta-Green et al., 2009).  
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Counseling Adherence. 
Counseling is a benefit to MAT (as opposed to receiving a prescription outside of 
maintenance treatment –an option for buprenorphine treatment) that provides individuals the 
opportunity to understand the disease and delve into the causes and consequences of their 
addiction (HHS, 2011). Counseling provides optimism and encouragement to overcome the 
addiction (HHS, 2011). Receiving on-site counseling was positively correlated to treatment 
retention in a research study, which integrated buprenorphine maintenance therapy at a Federally 
Qualified Health Center (FQHC) (Haddad, Zelenev & Altice, 2013). The study also indicated 
opioid use decreased as retention increased (Haddad et al., 2013). Since counseling is a benefit to 
MAT, adherence to counseling should be an indicator of successful treatment outcomes of MAT. 
Opioid Abstinence. 
Opioid abstinence is an indicator of successful MAT because continued opioid use in 
conjunction with MAT can create devastating effects for individuals, increasing the possibility of 
cardiovascular dysfunction, overdose, and mortality (Kelly et al., 2011). A comparison of heroin 
and prescription drug use dependents in a primary care office-based setting, concluded 
prescription opioid dependent patients were more likely to have negative urine screens (56.3% 
vs. 39.8%) (Moore et al., 2007). Opioid abstinence, reflective of a decrease in drug use is usually 
an indicator of longer engagement in treatment (Kelly et al., 2011; Franckowiak & Glick, 2015). 
Retention. 
Treating opioid dependence is similar to that of other chronic illnesses, yet it is often 
regarded as a semi-acute disorder (Vogel et al., 2017). Long-term care strategy principles, which 
are accepted for chronic illnesses -such as diabetes, and obesity- are still not widely accepted or 
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practiced for opioid use treatment (Vogel et al., 2017; McLellan, Lewis, O'Brien, & Kleber, 
2000). Engaging in treatment for an adequate time is crucial for treatment to be effective (NIDA, 
2011; Franckowiak & Glick, 2015). Studies have indicated patients in treatment for over a year 
are more likely to be productive citizens, and reduce high-risk behaviors (SAMHSA, 2013b; 
Kelly et al., 2011; Hubbard et al., 2003; Zhang, Friedmann, & Gerstein, 2003).  
Banta-Green et al. (2009) note although methadone maintenance treatment for heroin 
addicts have been assessed, there are limited studies on retention in treatment for prescription 
drug use. A comparison of retention of opioid (heroin and prescription drugs) dependents in 
Washington’s maintenance treatment programs, found no statistically significant difference in 
treatment retention (Banta-Green et al., 2009).  
Retention in MAT is an important outcome variable, as it correlates with long-term 
positive societal and treatment outcomes (Banta-Green, et al., 2009; Darker et al., 2016; Kelly et 
al., 2011). Retention in treatment decreases criminal involvement, increases education and social 
function, whereas treatment drop out may lead to relapse, and other high-risk behaviors (Darker 
et al., 2016; Compton & Volkow, 2006). Darker et al. (2016) notes that a higher rate in mortality 
occurs 30 days after drop-out, and a significant proportion of opioid dependents fail to stay in 
treatment.  
Possible Factors Associated with Treatment Outcomes 
Since MAT is a tool to prevent overdoses, abnormal cardiovascular function, and 




The characteristics of opioid dependents have changed from addicts in the past (Banta-
Green et al., 2009). In recent years, with the prescription drug misuse epidemic, the opioid 
dependence population has shifted to younger individuals, and there has been an increase in 
whites and females. Studies have asserted that personal characteristics are associated with 
treatment outcomes. However, there are disagreements in regard to gender, race, and relationship 
status in the literature, with age being the only exception in which there is agreement (Deck & 
Carlson, 2005; Joe, Simpson & Broom, 1998; Banta-Green et al., 2009; Darker et al., 2016; 
Kelly et al., 2011; Wasserman et al., 2001). 
Some studies have indicated the female gender as a predictor of positive treatment 
outcomes. In a survival analysis on retention in methadone treatment being female was a 
predictor of staying in treatment at 90 days (Kelly et al., 2011). Gender was a significant 
predictor in a retention study of methadone maintenance programs in Western states, where 
males were less likely to stay in treatment (Deck & Carlson, 2005). Gender was also 
significantly associated with opioid use during treatment in one study, with males less likely to 
abstain from opioids (Wasserman et al., 2001). However, another study found that gender was 
not one of the predictive demographic factors of treatment outcomes (Darker et al., 2016) 
Studies have found African Americans were less likely to stay in treatment in comparison 
to Whites and Latinos. African Americans were only half as likely to stay in treatment in the 
Washington sample from the two-Western state study (Deck & Carlson, 2005, p. 52). African 
Americans were 31% less likely to continue treatment in comparison to whites, with no 
significant differences between other races (Banta-Green et al., 2009, p. 778). Wasserman et al. 
(2001) also found African Americans significantly associated with being less likely to stay in 
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treatment, and to continue opioid abstinence. However, Kelly et al. (2011) found no statistical 
significance with race and treatment outcomes. 
Research has indicated age is positively associated with retention in treatment (Deck & 
Carlson, 2005; Darker et. al, 2016; Joe et al., 1998; Banta-Green et al., 2009; Wasserman et al., 
2001). Age was determined to be a significant predictor in a retention study of methadone 
maintenance programs in Western states (Deck & Carlson, 2005). In a binary logistic regression, 
age (being older) was significantly associated with retention (Darker et al., 2016). Banta-Green 
et al. (2009) noted 27% higher odds with every 10-year increase as a predictor for treatment 
retention.  
Limited studies have measured the association of relationship status to treatment 
outcomes. Being single appeared to be associated with not having breaks in treatment in the chi 
square analysis for an Ireland study, however the logistic regression indicated the relationship 
was not significant (Darker et al., 2016). Relationship status significantly differed in an analysis 
of variance (ANOVA), which measured days of opioid abstinence, with widows having longer 
days of abstinence (Cavaiola, Fulmer & Stout, 2015).  
Socio-economic Factors  
Socio-economic status (SES) is a significant element in relation to disease and treatment 
(Galea & Vlahov, 2002). Socio-ecological studies have noted the association with SES and 
poorer health outcomes – mortality, various health risks in drug users (Galea & Vlahov, 2002): 
“The existence of a social gradient, in which rates of morbidity and mortality decrease directly 
and proportionately with each increase in level of income or education (Galea & Vlahov, 2002, 
p. S137). Similar to personal characteristics, SES factors in drug abuse has shifted, with the 
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prescription drug misuse epidemic increasingly affecting the middle class (Banta-Green et al., 
2009; Moore et al., 2007). 
Few studies have researched SES as predictors of MAT treatment outcomes. When 
researching demographic and clinical factors as predictors in a study conducted in Ireland, 
employment and higher education were not predictors associated with retention in treatment 
(Darker et al., 2016). Income at entry and during treatment was not associated with treatment 
outcomes (Rash, Andrade & Petry, 2013; Rash, Olmstead, & Petry, 2009). Payment for services 
(self-pay, private or public insurance) is an access factor in health care systems. Patients with 
stable Medicaid eligibility were more likely to continue treatment - two and a half (2.5) times 
more likely in Oregon, and two-thirds more likely in Washington State (Deck & Carlson, 2005). 
Banta-Green et al. (2009) analysis also showed patients with public assistance funding -
Medicaid, TANF (Temporary Assistance for Needy Families)- were strongly associated with 
retention in treatment.  
Readiness to Change. 
Long-term behavioral changes require action and adjustments over time (Office of 
Behavioral and Social Sciences Research, n.d.). Motivation for treatment is an important aspect 
in treatment success (Harrell, Trenz, Scherer, Martins & Latimer, 2013). Opioid dependent 
individuals seeking treatment are at different stages in their ability to adopt a healthier behavior. 
Readiness to change is a construct within the transtheoretical model (TTM) (which will be 
discussed below) and includes 6 levels: pre-contemplation, contemplation, preparation, action, 
maintenance and termination (Prochaska & Velicer, 1997; Prochaska, Redding & Evers, 2002; 
Office of Behavioral and Social Sciences Research, n.d.). In researching predictors to retention 
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in treatment, at the 90-day interval a higher treatment readiness at admission was a predictor 
(Kelly et al., 2011). Harrell et al. (2013) in a latent class analysis noted patients in the “post-
action” phase were significantly more likely to abstain from opioids, whereas the pre-
contemplation class was significantly more likely to be positive for marijuana. Utilizing the 
URICA (the University of Rhode Island Change Assessment) to measure motivation in change, 
the assessment indicated individuals in the “committed action” stage were significantly 
associated with alcohol and cocaine abstinence (Pantalon, Nich, Frankforter & Caroll, 2002). 
Conversely, another study indicated no significance in readiness to change, but motivated 
patients had decreases in illicit drug use and crime (Nosyk et al., 2010). 
Support Systems. 
It is believed that social support plays an important role in health and recovery in general. 
Social support has shown to assist in the progression of treatment and abstinence from alcohol 
and drugs (Cavaiola et al., 2015; Franckowiak & Glick, 2015). However, disagreement exists in 
the literature in regard to social support improving treatment adherence and opioid abstinence. 
Cocaine abstinence was predicted when patients in opioid maintenance therapy had social 
support, but not opioid abstinence in a hierarchical logistic regression analysis (Wasserman et al., 
2001; Cavaiola et al., 2015). In addition, neither drug showed effects for general support on 
abstinence (Wasserman et al., 2001). Cavaiola et al. (2015) whose sample was mainly heroin and 
poly users (54.7% and 39.8% respectively), hypothesis was supported indicating social support 
was a predictor of longer periods of abstinence and readiness to change. Unlike in the past, 
recent research has shown those suffering with a substance use disorder usually have contact 
with a family member (Cavaiola et al., 2015). Social support may play a significant role in 
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assisting opioid abusers achieve abstinence, depending on the type of support received 
(Wasserman et al., 2001). 
Integrated Care. 
Integrated care models are emerging due to the “clinical promise” of better health 
outcomes and the cost effectiveness they contribute to both the patient and provider (Farber et 
al., 2012; Kelly et al., 2011). Cooker et al. asserts integration is “a spectrum of organizational 
arrangements relating to the funding, administration, organization, service-delivery and clinical 
scenarios designed to create connectivity, alignment and collaboration” (as cited in Topp et al., 
2013, p. 348). Substance use patients often lack the connectedness and treatment network to 
combat their illnesses; and often experience a high prevalence of additional medical disorders or 
shortages in basic care. Access to the availability of needed services has the potential to 
influence treatment outcomes. 
If not addressed as part of medical treatment, complications can arise, and can lead to 
reduction in treatment compliance (Farber et al., 2012). Integration of treatment services 
therefore allows for a more holistic care to the patient, encouraging prevention and continuum of 
care, in addition to more flexibility for the provider (Stone & Katz, 1996; Kelly et al., 2011; 
Franckowiak & Glick, 2015). A study on the impact of MAT on co-occurring patients indicated 
patients in integrated cognitive behavioral therapy in comparison to standard care had lower odds 
of positive opioid urine drug screens (Saunders, McGovern, Lambert-Harris, Meier, McLeman & 
Xie, 2015). The Community Access to Specialized Treatment (CAST) Initiative noted patients 
receiving integrated care were more compliant to counseling adherence (Neufeld et al., 2010).  
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Summary of Possible Factors Associated with Treatment Outcomes. 
Opioid dependence and treatment for the disease is complex. Few studies have examined 
the role of support systems and integrated care, in addition to personal characteristics and socio-
economic status on treatment outcomes in MAT (Heiman & Artiga, 2015; Galea & Vlahov, 
2002; Wasserman et al., 2001; Cavaiola et al. 2015). There are limited studies focusing on MAT 
outcomes, which primarily focus on non-medicinal prescription drug abuse opioid dependence 
(Timko et al., 2016). Additionally, prior studies included smaller sample sizes and variation in 
treatment outcomes. A need therefore exists to extend the literature on MAT programs for opioid 
dependence and fill a critical gap focusing on prescription drug abuse addicts. As the opioid 
epidemic has reached significant levels, in order to reduce mortality, it is important to understand 
factors that impact higher rates of retention and successful outcomes for a better quality of life.  
Theoretical Framework 
Social Cognitive Theory. 
Initially developed in the 1960s as the social learning theory, social cognitive theory 
(SCT) was developed in 1986 (Bandura, 1986). Social context within environmental, personal, 
and behavioral interaction are key constructs of the social cognitive theory (Office of Behavioral 
and Social Sciences Research, n.d.; Sharma, 2005). The distinct way in which individuals 
acquire and retain behavior in addition to the emphasis on social and environmental influences 
and key characteristics (Office of Behavioral and Social Sciences Research, n.d.; Sharma, 2005). 
The triangular model of the theoretical framework demonstrates the continual interaction of the 
three factors: personal, environmental and behavioral (Office of Behavioral and Social Sciences 
Research, n.d.; Sharma, 2005).  
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The primary constructs of SCT include: knowledge, self-efficacy, outcome expectations, 
goals, perceived facilitators, and impediments. Two of the domains SCT emphasizes for 
substance use behavioral change include: outcome expectancies and self-efficacy. The belief of 
specific behaviors resulting in certain outcomes (Gullo, Matveeva, Feeney, Young, & Connor, 
2017). Self-efficacy abstinence has received greater attention in relation to substance use 
treatment, in the ability to refuse or abstain from a substance. “Self-efficacy is a fundamental 
requirement for behavior change” (Sharma, 2005. p. 3). SCT recognizes exposures/beliefs play a 
pivotal role in consumption, dependence, and treatment (Gullo et al., 2017, p. 74). “Unless 
people believe that they can produce desired effects by their actions, they have little incentive to 
act or to persevere in the face of difficulties” (Bandura, 1999, p. 214). 
Transtheoretical Model. 
The transtheoretical model (TTM) emerged from theories in behavior change and 
psychotherapy (Prochaska et al., 2002). The core constructs of the model are stages of change, 
decisional balance, self-efficacy, and processes of change (Prochaska et al., 2002). This study 
incorporates the stages of change construct, which is commonly assessed in substance use 
treatment (Prochaska et al., 2002; Nosyk et al., 2010; Pantalon et al., 2002; Harrell et al., 2013). 
A temporal dimension is expressed in the stage construct, and change involves progress through 
the stages (Prochaska et al., 2002). Stages of change includes six stages: pre-contemplation, 
contemplation, preparation, action, maintenance, and termination. 
In this model, individuals in the initial stage, pre-contemplation, have no intentions in 
taking action or making changes within the next six months in the near future (Prochaska et al., 
2002). Contemplation stage includes those who intend to take action and make changes within 
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the next six months (Prochaska et al., 2002). Individuals in this stage are more aware of the 
advantages and disadvantages of their behaviors, and are often stuck in the difficult balance of 
the benefits and barriers (Prochaska et al., 2002, p. 100). Those in the preparation stage intend to 
take action within the next 30 days, usually have an action plan, and have made behavioral 
modifications (Prochaska et al., 2002). In the action stage, individuals have made observable 
behavior changes for less than six months, whereas individuals in the maintenance stage have 
made behavior changes for more than six months (Prochaska et al., 2002). In the final stage, 
patients have full self-efficacy and no matter their circumstance are confident in not returning to 
unhealthy habits (Prochaska et al., 2002).  
Theory of Reasoned Action. 
 To improve the understanding within a broader context, the theory of reasoned action is 
integrated with social cognitive theory as the theoretical base of the study. The theory of 
reasoned action predicts and discerns motivational influences on a behavior (Fishbein & Ajzen, 
1975; Madden, Ellen & Ajzen, 1992; Johnston, White & Norman, 2004). Created by Fishbein 
and Ajzen (1975), the theory was revised and extended as the theory of planned behavior to 
include perceived behavioral control. Behavioral intentions are a function of salient knowledge 
or beliefs about the probability that doing a particular behavior will lead to a distinct outcome 
(Fishbein & Ajzen, 1975; Madden et al., 1992; Millstein, 1996; McGinty & Anderson, 2008; 
Fleming et al., 2016; Johnston et al., 2004). Behavioral, and normative are the two initial 
constructs identified in the reasoned action approach (Fishbein & Ajzen, 1975; Madden et al., 
1992; Millstein, 1996; Fleming et al., 2016; Roberto, Shafer & Marmo, 2014; Rich, Brandes, 
Mullan & Hagger, 2015; Johnston et al., 2004). 
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Behavioral beliefs are the intrinsic influence on an individual’s attitude in performing the 
behavior, while the normative beliefs involve the subjective norms (Fishbein & Ajzen, 1975; 
Madden et al., 1992; Kleinman, Millery, Scimeca & Polissar, 2002). External elements affect 
intentions, but only to the extent of influencing either attitudes or subjective norms (Madden et 
al., 1992; Millstein, 1996). Therefore, the third belief, control was added. Control beliefs can 
guide or impede an individual from carrying out a behavior (Fishbein & Ajzen, 2010). Inclusive 
of environmental and personal factors, which facilitate positive outcomes in MAT; theory of 
reasoned action explains that an individual’s actions (i.e. counseling adherence, opioid 
abstinence, and retention) are the result of attitudes/behavior (treatment readiness), subjective 
norms (social support) and intentions towards that behavior (Fleming et al., 2016). 
Applications of the Theoretical Approach in Studies. 
The literature on social cognitive theory, transtheoretical model and the theory of 
reasoned action focuses on personal factors, elements in the environment and motivational 
influences that can shape the responses of opioid addicts in MAT. The empirical studies discuss 
survival and adoptions to innovations and necessary changes in the environment, in addition to 
attitudes, subjective norms, motivations and control resulting in specific behavior. Each of the 
studies emphasize at least one of the three core elements in the environment, stages of change, or 
behavioral constructs, which influence the response. Appendix B provides a table summary of 
the theoretical approaches literature review summary. Limited studies have utilized each theory 
as a theoretical framework to guide associations in MAT for opioid dependence. However, social 
cognitive theory and transtheoretical model has been utilized in addiction treatment research for 
cannabis, alcohol, nicotine, cocaine; and theory of reasoned action in addition to addiction 
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treatment research studies, has also been used in chronic illness studies. 
A socio-cognitive analysis of substance use hypothesized that self-efficacy (a domain of 
social cognitive theory) plays a key role in affecting every phase of treatment (initiation, 
recovery, relapse, long-term treatment) (Bandura, 1999). Having a greater belief in treatment 
success allows one to benefit more from treatment, and develop self-regulatory skills to succeed 
(Bandura, 1999). Environmental factors were noted as a motivator of relapse. Bandura (1999) 
therefore stressed the importance of a collective efficacy approach instead of an individualized 
approach in treating substance use.  
SCT was utilized as the framework to assess treatment outcomes and self-efficacy in a 
substance use study on cannabis dependence (Gullo et al., 2017). Emotional relief refusal self-
efficacy was a predictor of improved treatment outcomes; as abstinence increased with treatment 
sessions (1.20 times more likely) (Gullo et al., 2017). Self-efficacy is usually noted in relapse 
prevention approaches, influenced by social, personal and interpersonal key factors (Fiorentine 
& Hillhouse, 2011). Low controlled use of self-efficacy was a predictor of abstinence 
acceptance, which was associated with abstaining from drugs (Fiorentine & Hillhouse, 2011). 
The self-efficacy to change has also been associated with readiness to change. Utilizing 
the transtheoretical model to guide the framework of readiness for counseling and motivation to 
change with prescription-drug dependent patients, significant associations were seen in those 
with a higher readiness to change (p= .001) (Schmidt, Bischof, Harting & Rumpf, 2009). 
Majority of the patients (56%) were in pre-contemplation stage, with the others either in 
contemplation or in preparation stages (Schmidt et al., 2009). Patients in each stage group did not 
differ in their readiness for counseling (Schmidt et al., 2009). Examining readiness to change 
guided by TTM asserts readiness to change is a predictor of retention in methadone maintenance 
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treatment, and opioid abstinence (Kelly et al., 2011; Harrell et al., 2013). Pantalon et al. (2002) 
also associated a higher motivation to change with drug use abstinence.  
Prochaska and Velicer (1997) assert at-risk behaviors (opioid dependence) are usually in 
the initial three stages at the start of treatment. The majority is in pre-contemplation (40%) and 
contemplation stages (40%), followed by preparation (20%) (Prochaska & Velicer, 1997). 
Critical assumptions include, behavior change is a process, at-risk populations are not prepared 
for action, no one theory can account for the complex nature of behavior change, and chronic 
behavior patterns usually result from a combination of social, biological, and self-control 
(Prochaska & Velicer, 1997).  
 In researching predictors of long-term treatment for heroin and cocaine addicts entering 
detoxification Kleinman et al. (2002) asserts that the theory of reasoned action (in comparison to 
the other theoretical approaches constructs) was the most effective in predicting use of treatment 
programs. In the hierarchical multiple regression analysis, homelessness was the only significant 
predictor in the first stage, in addition to criminal justice involvement and fewer than 20 years 
using in the second stage (Kleinman et al., 2002). Behavioral beliefs and self-efficacy predicted 
treatment utilization on the third stage with the addition of four help-seeking variables 
(Kleinman et al., 2002).  
Rich et al. (2015) meta-analysis studied the variance of intention and behavioral 
outcomes for chronic illnesses. Inclusion studies had to examine health behaviors and/or 
treatment as recommended by a health care provider and explicitly comprised at least one 
construct of the theory (Rich et al., 2015). In regard to the effects of the theory constructs on 
adherence behaviors, the correlations were significant (p < .05) and had medium to large effect 
sizes. Perceived behavioral control, attitudes and subjective norms were statistically significant 
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predictors of intention and treatment adherence behavior (Rich et al., 2015). The theory 
explained 33% of variance in intention and 9% in adherence behavior (Rich et al., 2015). 
Roberto et al. (2014) confirmed the theory of reasoned action as a conceptual model for 
explaining attitudes and intentions and linkage of social norms in predicting substance-abuse 
treatment providers encouraging patients to use MAT as part of their treatment plan. Significant 
and substantial relationships were seen in each (behavior and intentions, attitudes and intentions, 
and norms and intentions. 
Conceptual Framework 
Social cognitive theory, transtheoretical model and the theory of reasoned action together 
provide a framework to understand the influence of factors on MAT outcomes. Figure 5 
illustrates the integrated elements and behavioral constructs for the theoretical framework 
conceptualized for the study.  
The conceptual framework as illustrated in Figure 5 incorporates the triangular model of 
SCT’s interaction of three elements: personal factors, environmental influences, and behavior. 
The framework integrates the transtheoretical model into personal factors and the theory of 
reasoned action into the three elements. The study will focus on the personal factors and 
behaviors (treatment outcomes) relationship, examining the interaction of personal influences 
and actions; in addition to the association of environmental influences and behaviors, looking at 




Figure 5. Conceptual Framework. This figure depicts an interwoven theoretical framework from 
social cognitive theory, transtheoretical model, and theory of reasoned action.  
 
The personal factors element incorporates individual characteristics, and factors which 
contribute beyond personal characteristics in particular, socio-economic status. Although 
individual behaviors are often associated with a wide range of factors that influence engagement 
or barriers to healthy behaviors and treatment, research has shown the conditions in the 
environment also affects risks and quality of life outcomes (Office of Disease Prevention and 
Health Promotion, 2017; Heiman & Artiga, 2015). Heiman and Artiga (2015) estimate that 60% 
of premature death risk is associated with individual behavior (40%) and social and 
environmental factors (20%). Social cognitive theory takes into account personal factors and 
social influences on the environment (internal and external) in understanding individuals’ 
behavior. 
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Readiness to change is the final variable in the personal factors element, taking from the 
stages of change construct in the transtheoretical model. This also incorporates the self-efficacy 
construct of SCT, in one’s ability to succeed. It measures the stage of participants in their 
readiness to receive treatment, and incorporates the attitudes element from the theory of reasoned 
action.  
The environmental influences encompass subjective norms (theory of reasoned action), 
and the physical environment. Subjective norms are the perceived social pressures to carry out a 
behavior (Azjen, 1991). Determining if having a support system or lack thereof during MAT 
may influence the treatment outcome. Access to the availability of needed services in the 
primary treatment location, is a physical environmental factor that also has the potential to 
influence behavior.  
Behavior is an element in both the social cognitive theory and theory of reasoned action. 
The outcome expectancies domain is a function of influences, knowledge and beliefs. Gullo et 
al., 2017 note SCT recognizes influences and exposures are crucial elements in dependence and 
treatment. The behaviors measured for treatment outcomes as discussed prior include counseling 
adherence, opioid abstinence, and retention in treatment.  
In summary, the conceptual framework indicates that personal factors (which 
incorporates personal characteristics, socio-economic factors, readiness to change) and 
environmental influences (subjective norms and physical environment) can impact behavior 
(treatment outcomes in MAT for opioid dependence). Utilizing the combined theoretical 




CHAPTER THREE: METHODOLOGY 
This section details the methodology used in the research study. The research questions and 
hypotheses are identified, the research design is explained, and a description of the population 
sample and variables are given. The ethical considerations of the study are also included. The chapter 
concludes with the data collection methods and analytical strategy used. 
Research Questions & Hypotheses 
The study aims to answer the following research questions derived from the literature and 
theoretical frameworks: 
Research Question 1: Are personal characteristics associated with treatment outcomes in MAT? 
Hypothesis 1A: Gender – identification as male is negatively associated with treatment 
outcomes. 
H1ACA: Male gender is negatively associated with treatment counseling 
adherence.  
H1AOA: Male gender is negatively associated with abstinence from opioids. 
H1AR: Male gender is negatively associated with retention in treatment 
Hypothesis 1B: Race - identification as African American is negatively associated with 
treatment outcomes. 
H1BCA: Identification as African American is negatively associated with 
treatment counseling adherence.  
H1BOA: Identification as African American is negatively associated with 
abstinence from opioids. 
H1BR: Identification as African American is negatively associated with retention 
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in treatment. 
Hypothesis 1C: Age is positively associated with treatment outcomes. 
H1CCA: Age is positively associated with treatment counseling adherence.  
H1COA: Age is positively associated with abstinence from opioids. 
H1CR: Age is positively associated with retention in treatment. 
Hypothesis 1D: Single relationship status is positively associated with treatment 
outcomes. 
H1DCA: Single - relationship status is positively associated with treatment 
counseling adherence.  
H1DOA: Single - relationship status is positively associated with abstinence from 
opioids. 
H1DR: Single - relationship status is positively associated with retention in 
treatment. 
Research Question 2: Are personal factors beyond characteristics, specifically socio-economic 
factors, associated with treatment outcomes in MAT patients? 
Hypothesis 2A: Higher education is positively associated with successful treatment 
outcomes in MAT patients.  
H2ACA: Higher education is positively associated with treatment counseling 
adherence.  
H2AOA: Higher education is positively associated with abstinence from opioids. 
H2AR: Higher education is positively associated with retention in treatment 
Hypothesis 2B: Employment is positively associated with successful treatment outcomes 
in MAT patients.  
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H2BCA: Employment is positively associated with treatment counseling 
adherence.  
H2BOA: Employment is positively associated with abstinence from opioids. 
H2BR: Employment is positively associated with retention in treatment. 
Hypothesis 2C: Having a higher income is positively associated with successful 
treatment outcomes in MAT patients.  
H2CCA: Higher income is positively associated with treatment counseling 
adherence.  
H2COA: Higher income is positively associated with abstinence from opioids. 
H2CR: Higher income is positively associated with retention in treatment 
Hypothesis 2D: Having health insurance is positively associated with successful 
treatment outcomes in MAT patients.  
H2DCA: Having health insurance is positively associated with treatment 
counseling adherence.  
H2DOA: Having health insurance is positively associated with abstinence from 
opioids. 
H2DR1: Having health insurance is positively associated with retention in 
treatment. 
H2DR2: Having public insurance (Medicaid) is positively associated with 
retention in treatment. 
Research Question 3: Is readiness to change associated with treatment outcomes in MAT 
patients? 
Hypothesis 3A: Readiness to change is positively associated with treatment outcomes in 
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MAT patients.  
H3ACA: Readiness to change is positively associated with treatment counseling 
adherence.  
H3AOA: Readiness to change is positively associated with abstinence from 
opioids. 
H3AR: Readiness to change is positively associated with retention in treatment. 
Research Question 4: Is having a support system associated with treatment outcomes in MAT 
patients? 
Hypothesis 4A: Having social support during treatment is positively associated with 
treatment outcomes in MAT patients. 
H4ACA: Having social support is positively associated with treatment counseling 
adherence.  
H4AOA: Having social support is positively associated with abstinence from 
opioids. 
H4AR: Having social support is positively associated with retention in treatment. 
Research Question 5: Is integrated care associated with treatment outcomes in MAT patients? 
Hypothesis 5A: Patients receiving integrated care are associated with positive treatment 
outcomes in MAT. 
H5ACA: Receiving integrated care is positively associated with treatment 
counseling adherence. 
H5AOA: Receiving integrated care is positively associated with opioid abstinence. 




A retrospective cohort research design was utilized in this study to examine the 
associations of personal factors (personal characteristics, socio-economic factors, and readiness 
to change) and environmental influences (support systems and integrated care) on treatment 
outcomes in MAT. Cohort studies examine specific sub-populations (opioid dependent 
individuals in MAT) over time (Babbie, 2014). Retrospective cohort studies are observational 
research designs, which examine prior data and investigate associations (risk or protective 
factors) to an outcome (Sedgwick, 2014). An advantage of this design is the assessment of the 
temporal sequence of factors and outcomes (Sedgwick, 2014). A limitation of this design is the 
observational nature of the study does not indicate causal pathways (Jeffers et al., 2015; 
Sedgwick, 2014). Observational or correlational research attempts to examine a relationship 
between two or more variables using statistical data but cannot assign causation (Babbie, 2014).  
Population & Sample 
The population was adults who sought treatment at an accredited not-for profit MAT 
program in West Florida. The not-for-profit behavioral health agency provides comprehensive 
community-based medical, substance use, mental health and HIV services reaching over 25,000 
individuals annually through prevention and treatment -detoxification, residential, intensive 
outpatient, outpatient, and medication-assisted treatment. The MAT program has doubled in 
admissions due to the prescription drug epidemic. Purposive sampling was utilized, specifically 
targeting individuals admitted to the MAT program during July 1, 2014 – June 30, 2016. 
Inclusion criteria includes a single episode of care for patients admitted during the study period. 
The final treatment episode was used for patients who re-entered treatment. With implementation 
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of the electronic health record (EHR), secondary data were retrieved from various sources within 
the EHR, as identified in the last column of Table 1, for patients enrolled in treatment during the 
study period.  
Setting. 
The MAT program provides services for adults (18 and older) seeking treatment for 
opioid dependence. Patients are self-referred, court-ordered, or referred from medical providers 
including pain management clinics, hospitals, and behavioral health programs. The program 
provides methadone, buprenorphine, or vivitrol medication treatment to control cravings and 
prevent withdrawals, while managing other medical conditions (onsite mental health, HIV and 
primary care services are available). Patients on vivitrol were not included in the study, as those 
patients’ records were not retrievable through the EHR. Patients also receive individualized 
counseling in addition to their medications.  
The program adheres to federal and state requirements for opioid treatment programs and 
is supervised by a licensed physician. A patient can only be admitted to treatment after a 
physician has determined the patient is physiologically addicted to opioid drugs for over a year 
(exceptions include penal, pregnant, and individuals with prior maintenance or detoxification 
treatment) (Florida Administrative Code, 2006). At the initial visit, patients complete a substance 
use and mental health assessment, which confirms an opioid dependence diagnosis using DSM-
V. Additionally, the ASAM (American Society of Addiction Medicine) placement criteria guides 
admission to the program. Patients may not be appropriate for outpatient treatment and referred 
to residential, intensive outpatient, or detoxification. The current study focuses on patients in 
outpatient treatment.  
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Strict protocols exist for starting patients on a low dosage, which the medical staff then 
monitors, and adjusts if necessary to stabilize the patient. A urine drug screen (UDS) is collected 
at the initial visit and randomly throughout treatment, which patients are required to adhere to by 
calling the urine drug screen line daily. Patients agree during the initial treatment plan to meet 
with an assigned counselor to discuss treatment goals and prevent relapse. 
Ethics. 
Prior to the start of the study, an approval was received from the University of Central 
Florida’s Institutional Review Board (IRB) to conduct human research. A HIPAA (Health 
Insurance Portability and Accountability Act) Waiver of Authorization required by 45 CFR 
(Code of Federal Regulations) 164.508 for the use or disclosure of protected health information 
(PHI) was also received, since PHI was required to match the UDS labs in a separate system, and 
patients’ consent was not received. The initial IRB approval (SBE-17-13277) was received on 
July 5, 2017, and the modification approval inclusive of the HIPAA Waiver of Authorization 
(HRP-441) was received on July 27, 2017. 
Risks to subjects were minimized by securing and protecting identifiable information. 
Data were recoded for analysis and secured (password-protected) on the Agency’s server with 
only the researcher having access. All identifiable information was deleted once the recode was 
completed within the three-month time period specified in the IRB protocol. Data will only be 
reported in aggregate form, and the study’s data set will be deleted after the required retention 
period of 5 years. Additionally, a business associate agreement was signed with the Agency, in 
accordance with federal regulations governing the Confidentiality of Substance Use Disorder 
Patient Records, 42 CFR Part 2; 45 CFR Parts 142, 160, 162, and 164, and HIPAA. 
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Study Variables/ Measures 
Variables of interest were determined from previously working in the behavioral health 
field, and other analyses in the literature. Table 1 defines the operationalization of each variable 
in more detail. Independent variables are: personal characteristics (patient’s gender, race, age 
relationship status), socio-economic factors (education, employment status, income, and health 
insurance), readiness to change, support system (social support), and integrated care. Controls 
include: type of primary opioid dependence, criminal history, whether patients were court-
ordered, and the medication prescribed. The outcome variables of interest include: counseling 
adherence, opioid abstinence, and retention in treatment. 
Dependent Variables. 
Counseling Adherence: captures whether the patient adheres to the counseling 
sessions/visits agreed on in the treatment plan. Counseling adherence is a continuous variable 
measured in weeks for the survival analysis based on the last counseling session date from the 
date of admission. 
Opioid Abstinence: assessed by urine drug screen (UDS) results. A negative result will 
indicate a negative screen from opioid substances with the exception of methadone or 
buprenorphine. Opioid Abstinence is a continuous variable measured in days for the survival 
analysis based on negative urine drug screens. If screens were positive at admission, patients 
were given a window period depending on the substance used. For instance amphetamines can 
still be detected in UDS up to 48 hours after use, whereas diazepam can be detected up to 30 
days after (Moeller, Lee & Kissack, 2008).  
Retention: measured by the length of time patients are engaged in medication treatment 
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after admission. For those with multiple treatment episodes, the final treatment episode was used. 
Retention is a continuous variable measured in days for the survival analysis based on 
medication dosing. 
Independent Variables. 
 Personal Characteristics. There were four variables within this category: gender, race, 
age, and relationship status, reported by the patient at admission.  
Gender: was measured by the category the patient identifies as: 1= male, 2= 
female. Male gender was the reference variable for the gender category (females compared 
against). 
Race: was measured by the category the patient identifies as: 1= White, 2= Black 
or African American (AA), 3= Other at admission. White was the reference variable.  
Age: A continuous variable of the patient’s age, based on date of birth at time of 
admission. 
Relationship status: was measured as reported by the patient at admission in the 
following categories: 1= single, 2= married, 3= other. Other is inclusive of patients who were 
divorced, separated, or widowed. Being single was the reference variable for the relationship 
status category. 
Socio-economic Factors. There were four variables within this category: education, 
employment, income and health insurance 
 Education: was coded by the highest education level completed at admission. 
Categories include 1= less than high school diploma, 2= high school diploma/GED (General 
Equivalency Diploma), 3= vocational training, 4= some college, 5= college degree inclusive of 
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any college degree attained. The lowest level attained, less than a diploma (elementary, middle 
or high school), was the reference variable.  
Employment: was coded by patient’s employment status at admission. 1= 
unemployed, 2= not in the workforce, 3= part-time, 4= full-time. Not in the workforce category 
was comprised of students, home-makers, those retired, disabled, on a leave of absence, or not 
authorized to work. Unemployment was the reference variable. 
Income: A continuous variable of the patient’s income at admission. 
Health insurance: was based on patient’s payment method for services rendered 
whether they had insurance or assistance. Patients were coded as 1= none, 2= public, 3= private. 
Public included Veterans and Medicaid patients, as well as those receiving assistance from 
federal and state funds or grants. Self-pay patients, those with no insurance was the reference 
category. 
Readiness to Change. This was assessed using the URICA (University Rhode Island 
Change Assessment Scale) by the intake counselor. The scoring of the URICA and categories 
was inclusive of four phases. 1= pre-contemplation, 2= contemplation, 3= action, and 4= 
maintenance. Pre-contemplation was the reference variable. 
 Social Support. This was measured by patient’s report on having a support system during 
their initial assessment. The two categories were 1= no, 2= yes. Having no support was the 
reference variable. 
 Integrated Care. Patients who received additional services (i.e. mental health, HIV) 
integrated in to MAT during care was measured by 1= no, 2= yes. Having no integrated care was 
the reference variable  
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Controls.  
 There were four variables within this category: opioid dependence, criminal history, court 
ordered, and medication. 
 Primary Drug Dependence. At admission, patients reported their primary drug of choice. 
Categories included 1= prescription medications, 2= heroin, 3= cocaine/crack, 4= 
methamphetamine, 5= other. Prescription medications are narcotics, tranquilizers, and 
amphetamines. The reference variable was prescription drugs.  
Criminal History. Criminal history is self-reported at admission, based on the patients’ 
recollection of prior criminal record. The two categories were 1= no criminal history, 2= yes for 
patients with a history. No criminal history was used as the reference variable. 
Court Ordered. The intake counselor verified the referral source and indicated if the 
patient was court-ordered to treatment. Patients were coded as 1= no (not court ordered) versus 
2= yes (court-ordered to treatment). Not court-ordered was the reference category. 
Medication. Categorized by the prescribed medication the patient received on initial 
admission to the clinic. The medication prescribed was coded as 1= Methadone, 2= 




Table 1  
 
Operational Definitions of the Study Variables  
Variables Type Definition Measure Data Source 
Counseling 
adherence 
Dependent Length of time patient 
adhered to counseling 
sessions agreed upon in 









Dependent Length of time patient 
abstained from opioids 




Retention  Dependent Length of time patient 
is receiving medication 
Continuous 
SA: days  
Admission 




Independent Gender the patient 
identifies as at 
admission 
Categorical (2): 






Independent Race the patient 
identifies as at 
admission 
Categorical (3): 







Independent Age of the patient at 
admission 





Independent Relationship status as 









Independent Highest education level 
completed by the 
patient at admission 
Categorical (5): 




3= vocational, 4= 






Independent Patient’s employment 
status at admission 
Categorical (4): 
1= unemployed*, 






factor:   
Income 








Independent Patients form of 
payment for services 
Categorical (3): 
1= None*, 2= 





Independent Patient’s stage of 






3= action, 4= 
maintenance 
Admission,  
Social Support Independent Patient’s report of 
support systems during 
initial assessment  
Categorical (2): 
1= no*, 2=yes 
Admission, 
PSA 
Integrated Care Independent Patients who received 
additional services 
integrated into MAT 
treatment – HIV, MH, 
Medical 
Categorical (2): 






Control  Drug dependence at 




heroin, 3= crack/ 
cocaine, 4= 
methamphetamin
e, 5= other  
Admission  
Criminal History Control Criminal history 
reported at time of 
admission 
Categorical (2): 
1= no*, 2=yes 
 
Admission 
Court Ordered Control Patient court-ordered to 
treatment 
Categorical (2): 
1= no*, 2=yes 
Admission 
Medication Control  Medication prescribed 




2= buprenorphine  
Medical 
Order 
* Reference variable 
 
Data Collection 
Permission to gain access to secondary data from the MAT Programs in West Florida was 
granted in December 2016 by the Chief Executive Officer pending IRB approval. The Chief 
Executive Officer provided a letter of support to conduct the study (see Appendix C), and 
requested that a confidentiality clause is included to protect substance use patients in adherence 
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with HIPAA and 42 CFR Part 2 the Confidentiality of Alcohol and Drug Abuse Patient Records 
when completing the IRB protocol. With the merging of data sets for the urine drug screens, in 
addition to cleaning and verifying any data needed, it was important to ensure the confidentiality 
of patients’ health information. After IRB approval was received, data were obtained from three 
systems that comprise the electronic health record (EHR) on September 6, 2017. Comprehensive 
questions in the admission, psychosocial assessment, treatment planning and discharge were 
used for the study variables.  
Data Analysis 
Data were analyzed using the Statistical Package for Social Sciences (SPSS) Program. 
Data were first cleaned and coded to detect and remove errors for ensuring appropriate statistical 
analysis. The initial data set included 5979 cases. However, the majority were duplicates which 
had to be removed. Since the data were received in September, the data set also included 
admissions beyond the study period which also had to be removed. Additionally, only the last 
treatment of care was used for patients with multiple admissions. Univariate descriptive statistics 
(measures of central tendency, dispersion and distribution) and identification of missing data 
were then analyzed. In terms of missing values, SPSS uses pairwise exclusion which excludes 
cases when data are missing for the particular analysis. 
Bivariate statistical tests -correlations and ANOVA- examined the relationships between 
the dependent (counseling adherence, opioid abstinence, and retention) and independent 
variables. The covariates were analyzed for multicollinearity to ensure predictor variables do not 
impact the models. Multicollinearity is not a concern when the independent variables are not 
highly correlated (r =.8 or above) or when the variance inflation factor (VIF) is under 4.0 or 
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tolerances are above 40. Since the variables being measured were time-dependent, the Kaplan 
Meier Method was conducted to demonstrate the bivariate relationships, and cox regression 
models for the multivariate analysis.  
Survival Analysis. 
 Survival analysis studies illustrate the time it takes for an event of interest to occur 
(Kleinbaum, & Klein, 2005; Fox & Weisberg, 2011; Despa, n.d.; Parmar & Machin, 1995; 
Allison, 2014). In addition to the time variable, survival analysis also includes censoring. A 
paramount feature which accounts for observations when the survival time is incomplete 
(Allison, 2014; Despa, n.d.) Right censored depicts patients who do not experience the event 
during the study (Allison, 2014; Kleinbaum & Klein, 2005; Despa, n.d.). This also accounts for 
missing data. Random and non-informative censoring is required to avoid bias in a survival 
analysis (Kleinbaum & Klein, 2005). 
Utilizing the wrong model and violating assumptions can lead to false inferences about 
the regression (Allison, 1999). Since survival times are usually positive, using linear regression 
would not be the optimum choice (Allison, 2014; Despa, n.d.). Regression techniques such as 
ordinary least squares (OLS) cannot adequately handle censored observations, which survival 
analysis incorporates in estimating important model parameters (Allison, 2014; Kleinbaum & 
Klein, 2005; Despa, n.d., p. 1).  
Kaplan Meier Method. 
 The Kaplan Meier Method estimates and illustrates survival probabilities as a function of 
time (Despa, n.d., p. 2; Kleinbaum & Klein, 2005). It provides descriptive and bivariate statistics 
of the variables.  
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Cox (Proportional Hazards) Regression. 
The cox regression model is the most widely used model providing information on the 
hazard function to predictors (Kleinbaum & Klein, 2005; Fox & Weisberg, 2011). The model 
examines the relationship between survival (dependent variables – counseling adherence, opioid 
abstinence, and retention in treatment up to 365 days/ 52 weeks) and predictors.  
Survival function is denoted as the probability a patient “survives” longer than a specified 
time, S(t) = P (T > t) (Kleinbaum & Klein, 2005). While the hazard function provides the 
“instantaneous potential per unit time for the event to occur; given that the individual has 
survived up to time “t” and is considered the conditional failure rate (Kleinbaum & Klein, 2005, 
p. 10). One function can be derived knowing the other, although on opposing ends (Kleinbaum & 
Klein, 2005). The hazard function centers on failing, whereas surviving is the focus of the 
survivor function.  
ℎ(𝑡) = lim
∆𝑡→0




T= survival time (dependent variables) 
t= specified value of t (52 weeks – counseling adherence, 365 days – opioid abstinence and 
retention) 
The cox proportional-hazard equation: 
ℎ𝑖(𝑡) = ℎ𝑜(𝑡) exp(𝛽1𝑋𝑖1 + 𝛽2𝑋𝑖2 +  … + 𝛽𝑘 𝑋𝑖𝑘) 
Where:  
hi (t) = hazard rate at time t 
h0 (t) = baseline hazard 
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β1 – 15 = regression coefficients 
X = predictor variables 
 X1 = Personal Characteristics – gender  
 X2 = Personal Characteristics – race 
 X3 = Personal Characteristics – age 
 X4 = Personal Characteristics – relationship status 
 X5 = Socio-economic Factors – education 
 X6 = Socio-economic Factors – employment 
 X7 = Socio-economic Factors – income 
 X8 = Socio-economic Factors – health insurance 
 X9 = Readiness to Change  
 X10 = Social Support  
 X11 = Integrated Care 
 X12 = Opioid Dependence 
 X13 = Criminal History 
 X14 = Court Ordered 
 X15 = Medication  
Power Analysis. 
 A priori power analysis determines if the expected sample is large enough to support this 
analysis achieving desired effect size. Determination of minimum sample size is needed to make 
generalizations to the population. Power is the odds of observing an effect when it occurs 
(Farrokhyar, Reddy, Poolman & Bhandari, 2013). A priori power equation includes sample size 
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(number of units in the study), effect size (salience of treatment relative to noise), number of 
predictors, and alpha level (odds that observed results are due to chance). Power = f(sample size, 
effect size, number of predictors, alpha). With an anticipated effect size of 0.15, power level of 
.8, 41 predictors and a probability level of .05, the priori power analysis indicated a minimum 
sample size of 216 is required to reach statistically significant results.  
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CHAPTER FOUR: RESULTS 
 The results section provides a detailed description of the analyses completed. The chapter 
begins with a depiction of the study sample, then continues with the bivariate and survival 
analyses conducted. The chapter concludes with an interpretation of the hypotheses testing.  
Descriptive Analysis 
The sample consisted of 1151 adults receiving MAT during the study period from July 1, 
2014 to June 30, 2016. As shown in Table 2, the sample was predominantly female (61.4%), 
White (86.6%) and single (68.2%). The mean age at time of admission was 34.72 years (standard 
deviation = 9.926) ranging from 18 to 76 years. Almost 30% of the participants’ highest level of 
education was less than a high school diploma or GED, 39.9% received a high school diploma or 
GED, 3.4% completed vocational training, 17.2% completed some college courses, and 9.8% 
had a college degree. The majority of participants were unemployed (56.9%), therefore the mean 
income at time of admission was $825.29 (standard deviation = 5131.61). The majority of the 
sample had some form of insurance or coverage -public 55% and private 9.4%- while 35.6% of 
patients had no insurance and were considered self-pay. For the final variable under personal 
factors, readiness to change, 29.5% of patients were in the initial phase of pre-contemplation at 
intake, 34.8% in contemplation, 24.2% in action, and 11.5% were in the maintenance stage. In 
terms of variables under environmental factors, the majority of patients 87.1% had some form of 
social support, and 37.8% had received integrated care. 
The study included four control variables: primary drug dependence, criminal history, 
being court-ordered to treatment, and medication prescribed. The majority of patients had a 
primary drug addiction to non-medicinal prescription drugs (68.1%) or heroin (27.7%), had no 
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criminal history (81.5%), were not court ordered to treatment (93.4%) and were prescribed 
methadone (93%). 
In addition to the mean and standard deviation, the median is also reported due to the 
normal curve being skewed for the three dependent variables which were time-dependent. 
Counseling adherence measured in weeks had a median of 38.43 weeks, and mean of 32.80 
(standard deviation = 20.104). Opioid abstinence measured in days had a 77.21 median and mean 
of 139.47 (standard deviation = 131.230). Retention was also measured in days had a 182.50 
median, and mean of 202.91 (standard deviation = 136.520). Detailed characteristics of the 




N= 1151 N  % Median  Mean  (SD) 
Gender 
   Male 







   
Race 
   White 
   Black/AA 









   
Age   33.00 34.72 9.926 
Relationship Status 
   Single 
   Married 









   
Education 
   < high school 
   High school 
   Vocational 
   Some college 













   
Employment 
   Unemployed 
   Not-in workforce 
   Part-time 
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N= 1151 N  % Median  Mean  (SD) 
Income   0.00 825.29 5131.613 
Insurance 
   None    
   Public 









   
Readiness to Change 
   Pre-contemplation 
   Contemplation 
   Action 











   
Support System 
   No    







   
Integrated Care 
   No    







   
Drug Dependence  
   Prescriptions 
   Heroin 
   Crack/Cocaine 
   Methamphetamine 













   
Criminal History 
   No 







   
Court. Ordered 
   No 







   
Medication Prescribed 
   Methadone 







   
Counseling Adherence 










   (days) 







   (days) 









Comparisons between continuous variables were analyzed using the Pearson correlation 
coefficient (r). For categorical variables, the means of the dependent variables were compared 
between groups, using the Fischer’s test (F). For statistical significant differences between 
groups of three or more, the post-hoc comparisons using the Tukey HSD test was analyzed.  
Correlation.  
As depicted in Tables 3, 4 and 5, there were no significant correlations between the 
continuous independent variables (age and income) with the dependent variables.  
 
Table 3  
 
Correlations between counseling adherence and continuous independent variables 
Variable N R P-value 
Age 623 .058 .145 
Income 445 -.012 .802 
 
Table 4  
 
Correlations between opioid abstinence and continuous independent variables 
Variable N R P-value 
Age 1118 .027 .370 




Correlations between retention and continuous independent variables 
Variable N R P-value 
Age 1066 .038 .214 




Counseling Adherence: Table 6 shows the results of ANOVAs conducted to explore the 
impact of independent categorical variables on counseling adherence in mean weeks. There were 
no statistically significant differences between the means of any of the personal characteristic 
variables –gender, race, relationship status. 
All of the socio-economic factors, with the exception of insurance, had no statistical 
significance as well. There was a statistically significant difference in counseling adherence time 
for the three insurance groups: F(2, 623)= 14.380, p=.000. Post hoc comparisons using the Tukey 
HSD test indicated that the mean score for no insurance (M = 26.44, SD = 19.927) was 
significantly different from public insurance (M = 35.72, SD = 19.567) but did not differ 
significantly from private insurance (M = 27.29, SD = 19.938).  
For the final personal factor, readiness to change was not statistically significant.  
In regard to environmental influences, having a support system was not statistically 
significant. There was a statistical significant difference in those who had integrated care and 






ANOVA of Counseling Adherence and the categorical independent variables 
Variable N Mean 
(weeks) 
SD F p-value 
Gender 
   Male 












   White 
   Black/AA 















   Single 
   Married 















   < high school 
   High school 
   Vocational 
   Some college 





















   Unemployed 
   Not-in workforce 
   Part-time 


















   None    
   Public 














Readiness to Change 
   Pre-contemplation 
   Contemplation 
   Action 


















   No    












   No    
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Variable N Mean 
(weeks) 
SD F p-value 
Drug Dependence  
   Prescriptions 
   Heroin 
   Crack/Cocaine 
   Methamphetamine 





















   No 












   No 












  Methadone 











* Statistical significance, p  .05 
 
Opioid Abstinence: Table 7 details the results of ANOVAs conducted to explore the 
impact of independent categorical variables on opioid abstinence in mean days. There was no 
statistical significance between the means of any of the personal characteristic variables –gender, 
race, relationship status with opioid abstinence.  
There was also no statistical significance for education. There was a statistical significant 
difference in opioid abstinence days for the four employment groups: F(3, 820)= 3.2200, p=.022. 
Post hoc comparisons using the Tukey HSD test indicated there was only one significant 
difference between the four employment categories, unemployed patients (M = 135.39, SD = 
128.336) and patients who worked full-time (M = 176.52, SD = 146.166). 
Having some form of insurance had statistical significance with opioid abstinence: F(2, 
1118)= 18.3700, p=.000. Post hoc comparisons using the Tukey HSD test indicated that the 
mean score for no insurance (M = 109.32, SD = 114.748) was significantly different from public 
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insurance (M = 151.32, SD = 135.362) and private insurance (M = 180.53, SD = 141.820). 
However, there was no statistical significant difference in public and private insurance.  
Readiness to change had no statistical significance with opioid abstinence.  
For environmental influences, there was a statistically significant difference between 
those who had social support: F(1, 1118)= 17.968, p=.000, and those who did not. In addition, 
patients who received integrated care and those who did not had a statistical difference in opioid 
abstinence days: F(1, 1118)= 11.763, p=.001. 
Control variables indicated two significant differences between means in opioid 
abstinence days. There was a statistical significant difference in primary drug dependence for the 
five groups: F(4, 895)= 4.883, p=.001. Post hoc comparisons using the Tukey HSD test indicated 
only two groups differed significantly from each other, prescription drugs (M = 148.41, SD = 
133.448) and heroin  (M = 117.10, SD = 122.836). Prescribed medications also indicated a 
statistical significance between means for methadone and buprenorphine medications: F(1, 




ANOVA Analysis of Opioid Abstinence and categorical independent variables 
Variable N Mean (days) SD F p-value 
Gender 
   Male 












   White 
   Black/AA 















   Single 
   Married 















Variable N Mean (days) SD F p-value 
Education 
   < high school 
   High school 
   Vocational 
   Some college 





















   Unemployed 
   Not-in workforce 
   Part-time 


















   None    
   Public 














Readiness to Change 
   Pre-contemplation 
   Contemplation 
   Action 


















   No    












   No    











Drug Dependence  
   Prescriptions 
   Heroin 
   Crack/Cocaine 
   Methamphetamine 





















   No 












   No 












  Methadone 











* Statistical significance, p  .05 
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Retention: Table 8 shows the results of ANOVAs conducted to explore the impact of 
independent categorical variables on retention. There was no statistical significance between the 
means of any of the personal characteristic variables -gender, race, relationship status- and socio-
economic variables -education, and employment- and retention, with the exception of insurance. 
Insurance had a statistically significant difference in means for the three groups –none, public, 
private: F(2, 1066)= 53.629, p=.000. Post hoc comparisons using the Tukey HSD test indicated 
that the mean score for no insurance (M = 146.71, SD = 123.167) was significantly different 
from public insurance (M = 233.15, SD = 133.145) and private insurance (M = 234.09, SD = 
138.778). However, there was no statistically significant difference in public and private 
insurance.  
Readiness to change had no statistical significance with retention.  
There was a statistically significant difference in those who had a support system F(1, 
1066)= 9.561, p=.002, and those who did not. In addition, patients who received integrated care 
and those who did not had a statistical difference between means in opioid abstinence days (1, 
1118)= 71.975, p=.000. 
Control variables indicated two significant differences between means in retention days. 
There was a statistically significant difference in patients who had a criminal history and those 
who did not: F(1, 822)= 4.703, p=.030. Prescribed medications also indicated a statistical 





ANOVA Analysis of Retention in treatment and categorical independent variables 
Variable N Mean (days) SD F p-value 
Gender 
   Male 












   White 
   Black/AA 















   Single 
   Married 















   < high school 
   High school 
   Vocational 
   Some college 





















   Unemployed 
   Not-in workforce 
   Part-time 


















   None    
   Public 

















Readiness to Change 
   Pre-contemplation 
   Contemplation 
   Action 


















   No    












   No    
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Variable N Mean (days) SD F p-value 
Drug Dependence  
   Prescriptions 
   Heroin 
   Crack/Cocaine 
   Methamphetamine 





















   No 












   No 












  Methadone 











* Statistical significance, p  .05 
Survival Analysis 
Kaplan Meier Method. 
The Kaplan-Meier survival curves of the treatment outcomes are illustrated only for 
selected factors with significant associations and the detailed results are included in Table 9. For 
each covariate the table includes the percentage for each category that met the survival goal (52 
weeks or 365 days), the median survival time, chi-square, and significance. The Log rank 
(Mantel-cox) was used for the chi-square, since it focuses on events that occur later on within the 
timeframe (Kleinbaum & Klein, 2005). Since none of the curves were normal for the dependent 
variables, the median (versus the mean) was used for the estimated survival time rounded to the 





Kaplan Meier table of covariates and treatment outcomes.  
 Counseling 
Adherence 
Opioid Abstinence Retention 
Gender 
   Male 
   Female 
 
38.9%, est. 34 weeks 
46.1%, est. 42 weeks 
x2 (1, N=623)= 
2.230, p=.135  
 
17.9%, est. 66 days 
16.7%, est. 79 days 
x2 (1, N=1118)= 
.037, p=.848 
 
29.7%, est. 180 days 
33.07%, est. 183 days 
x2 (1, N=1066)= 
.473, p=.492 
Race 
   White 
   Black/AA 
   Other 
 
43.4%, est. 38 weeks 
50.0%, est. 43 weeks 
37.5%, est. 36 weeks 
x2 (2, N= 619)= 
1.055, p=.590 
 
16.8%, est. 79 days 
22.0 %, est.62 days 
19.0%, est. 50 days 
x2 (2, N= 1107) = 
.583, p= .747 
 
32.5%, est. 184 days 
33.3%, est. 209 days 
24.1%, est. 132 days 
x2 (2, N=1055)= 
4.608, p= .100 
Relationship Status 
   Single 
   Married 
   Other 
 
45.7%, est. 42 weeks 
42.3%, est. 33 weeks 
40.2%, est. 34 weeks 
x2 (2, N= 612)= 
1.464, p= .481 
 
16.6%, est. 75 days 
20.1%, est. 78 days 
14.2%, est. 85 days 
x2 (2, N= 1103)= 
.157, p= .924 
 
31.3%, est. 176 days 
34.8%, est. 194 days 
27.9%, est. 175 days 
x2 (2, N= 1054)= 
1.131, p=.568 
Education 
   < high school 
   High school  
   Vocational 
   Some college 
   College Degree 
 
50.0%, est. 47 weeks 
46.4, est. 43 weeks 
50.0, est. 44 weeks 
37.2, est. 26 weeks 
42.9, est. 47 weeks 
x2 (4, N=473)= 
3.190, p= .527 
 
15.2%, est. 73 days 
22.5%, est. 90 days 
17.9%, est. 165 days 
12.9%, est. 62 days 
16.5%, est. 109 days 
x2 (4, N= 815)= 
8.174, p= .085 
 
29.1%, est. 175 days 
37.6%, est. 222 days 
26.9%, est. 196 days 
24.4%, est. 176 days 
37.8%, est. 260 days 
x2 (4, N= 775)= 
8.514, p= .074 
Employment 
   Unemployed 
   Not-in workforce 
   Part-time 
   Full-time 
 
43.7%, est. 36 weeks 
47.4%, est. 48 weeks 
50.0%, est. 35 weeks 
47.8%, est. 48 weeks 
x2 (3, N= 476)= 
1.673, p= .643 
 
16.7%, est. 73 days 
17.8%, est. 74 days 
11.1%, est. 118 days 
26.2%, est. 119 days 
x2 (3, N= 820)= 
7.271, p= .064 
 
30.2%, est. 178 days 
36.0%, est. 229 days 
41.9%, est. 212 days 
32.1%, est. 234 days 
x2 (3, N= 780)= 
3.982, p= .263 
Insurance 
   None    
   Public 
   Private 
 
28.4%, est. 24 weeks 
50.8%, est. 33 weeks  
27.9%, est. 27 weeks 
x2 (2, N= 623)= 
33.641, p= .000* 
 
9.6%, est. 52 days 
20.2%, est. 91days  
27.2%, est. 164 days 
x2 (2, N= 1118)= 
37.823, p= .000* 
 
14.2%, est. 93 days 
41.3%, est. 261 days  
41.3%, est. 307 days 
x2 (2, N= 1066)= 
120.975, p= .000* 
    




Opioid Abstinence Retention 
Readiness to Change 
   Pre-contemplation 
   Contemplation 
   Action 
   Maintenance 
 
45.0%, est. 43 weeks 
48.3%, est. 49 weeks  
37.6%, est. 33 weeks 
50.7%, est. 35 weeks 
x2 (3, N= 578)= 
4.189, p= .242 
 
18.8%, est. 77 days 
17.5%, est. 73 days  
12.4%, est. 73 days 
19.3%, est. 82 days 
x2 (3, N= 1021)= 
4.509, p= .211 
 
32.5%, est. 178 days 
32.5%, est. 172 days  
28.6%, est. 183 days 
35.9%, est. 245 days 
x2 (3, N= 979)= 
1.986, p= .575 
Support System 
   No    
   Yes 
 
43.3%, est. 38 weeks 
44.6%, est. 43 weeks 
x2 (1, N= 623)=.116,  
p= .733 
 
15.7%, est. 70 days 
26.7%, est. 170 days 
x2 (1, N= 1118)= 
13.297, p= .000* 
 
31.2%, est. 170 days 
35.9%, est. 242 days 
x2 (1, N= 1066)= 
4.859, p= .028* 
Integrated Care 
   No    
   Yes 
 
39.8%, est. 32 weeks 
47.9%, est. 44 weeks 
x2 (1, N= 623)= 
5.548, p= .019* 
 
15.9%, est. 64 days 
19.2%, est. 108 days 
x2 (1, N= 1118)= 
9.370, p= .002* 
 
26.5%, est. 122 days 
40.4%, est. 275 days 
x2 (1, N= 1066)= 
48.188, p= .000* 
Drug Dependence  
   Prescriptions 
   Heroin 
   Crack/Cocaine 
   Methamphetamine 
   Other 
 
47.7%, est. 48 weeks 
38.5%, est. 33 weeks 
62.5%, est.      weeks  
50.0%, est. 34 weeks  
50.0%, est. 16 weeks  
x2 (4, N= 515)= 
3.793, p= .435 
 
19.3%, est. 85 days 
12.1%, est. 51 days 
30.0%, est. 79 days 
50.0%, est. 300 days 
23.8%, est. 202 days 
x2 (4, N= 895)= 
19.255, p= .001* 
 
34.2%, est. 194 days 
25.0%, est. 183 days 
50.0%, est. 281 days 
80.0%, est.        days 
40.0%, est. 201 days 
x2 (4, N= 854)= 
7.758, p= .101 
Criminal History 
   No 
   Yes 
 
45.7%, est. 43 weeks 
42.0%, est. 35 weeks 
x2 (1, N= 498)= .355, 
p= .551 
 
18.8%, est. 81 days 
14.2%, est. 83 days 
x2 (1, N= 862)= .993, 
p= .319 
 
33.4%, est. 208 days 
26.6%, est. 160 days 
x2 (1, N= 822)= 
4.598, p= .032* 
Court. Ordered 
   No 
   Yes 
 
45.6%, est. 43 weeks 
42.9%, est. 34 weeks 
x2 (1, N= 515)= .046, 
p= .830 
 
17.9%, est. 78 days 
15.5%, est. 134 days 
x2 (1, N= 895)= .720, 
p= .396 
 
32.3%, est. 194 days 
32.8%, est. 183 days 
x2 (1, N= 854)= .589, 
p= .443 
Medication  
   Methadone 
   Buprenorphine 
 
45.0%, est. 41 weeks 
10.7%, est. 28 weeks 
x2 (1, N= 623)= 
7.374, p= .007* 
 
16.1%, est.72 days 
39.2%, est. 322 days 
x2 (1, N= 1118)= 
22.430, p= .000* 
 
30.9%, est.176 days 
57.1%, est.  days 
x2 (1, N= 1066)= 
10.921, p= .001* 
* Statistical significance, p  .05 
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There were no statistically significant associations with personal characteristics and 
treatment outcomes. Health insurance was the only socio-economic factor which showed an 
association with all three dependent variables. Figures 6, 7 and 8 show the curve of counseling 
adherence, opioid abstinence and retention respectively by health insurance. Relative to 
counseling adherence, patients with public coverage have a higher survival probability than those 
with private or no insurance (Log-rank statistic = 33.641, p = .000). Opioid abstinence on the 
other hand, initially showed a similar probability among all three categories in the first 50 days. 
However, as time progressed, those with private coverage had a higher probability than those 
with public assistance, followed by those with no insurance with the lowest survival probability 
to abstain from opioids (Log-rank statistic = 37.823, p = .000). Patients’ retention in treatment 
was higher if they had either public or private insurance than if they had none. (Log-rank statistic 
= 120.975, p = .000). Median survival time was over 240 days for patients with either type of 




Figure 6. Insurance and Counseling Adherence. This figure illustrates the Kaplan Meier survival 
curve on the association of insurance and counseling adherence. 
  
 
Figure 7. Insurance and Opioid Abstinence. This figure illustrates the Kaplan Meier survival 




Figure 8. Insurance and Retention. This figure illustrates the Kaplan Meier survival curve on the 
association of insurance and retention.  
 
For environmental influences, there were associations for both covariates. There was a 
statistically significant association with social support and two of the dependent variables-opioid 
abstinence and retention. Figure 9 illustrates patients with social support having a higher survival 
probability than those without, in abstaining from opioids (Log-rank statistic = 13.297, p = .002). 
The median survival time was 170 days for those with social support versus those without social 
support at 70 days. Similarly, a higher probability in survival time was seen in relation to 
retention and having social support. Figure 10 shows the survival probability for patients with 
social support having a higher survival probability than those without in relation to retention 
(Log-rank statistic = 4.859, p = .028). The median survival time was 242 days for those with 




Figure 9. Social Support and Opioid Abstinence. This figure illustrates the Kaplan Meier 
survival curve on the association of support systems and opioid abstinence. 
 
 
Figure 10. Social Support and Retention. This figure illustrates the Kaplan Meier survival curve 
on the association of support systems and retention.  
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Integrated care showed statistically significant associations with all dependent variables. 
Figures 11, 12, and 13 depicts the association of integrated care on counseling adherence, opioid 
abstinence and retention respectively in Kaplan Meier curves. In regard to counseling adherence, 
patients with integrated care have a higher survival probability than those without (Log-rank 
statistic = 5.548, p = .019). Opioid abstinence on the other hand, initially showed a similar 
probability among both categories in the initial month as seen in Figure 12. However, as time 
progressed those with integrated care had a higher probability than those without (Log-rank 
statistic = 9.370, p = .002). Patients’ retention in treatment had a much higher survival 
probability if they were in integrated care than not (Log-rank statistic = 48.188, p = .000). 
Median survival time of those with integrated care was 275 days versus 122 days for those 
without integrated care.  
 
Figure 11. Integrated Care and Counseling Adherence. This figure illustrates the Kaplan Meier 




Figure 12. Integrated Care and Opioid Abstinence. This figure illustrates the Kaplan Meier 
survival curve on the association of integrated care and opioid abstinence.  
 
 
Figure 13. Integrated Care and Retention. This figure illustrates the Kaplan Meier survival curve 




Finally, the control variables had three significant associations. The association of opioid 
abstinence and primary drug dependence showed a statistically significant association, as 
depicted in Figure 14. Those whose primary dependence was methamphetamine or other drugs 
have a higher survival probability in comparison to non-medicinal prescription drugs (median 
survival: 85 days) or heroin (median survival: 51 days) (Log-rank statistic = 19.255, p = .001). 
 
Figure 14. Primary Drug Dependence and Opioid Abstinence. This figure illustrates the Kaplan 
Meier survival curve on drug dependence and opioid abstinence. 
  
Those with no criminal history had a median survival of 208 days retained in MAT in 
comparison with 160 days for those with a criminal (Log-rank statistic = 4.598, p = .032). Figure 
15 shows the association of patient’s criminal history and retention. 
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Figure 15. Criminal History and Retention. This figure illustrates the Kaplan Meier survival 
curve on the association of criminal history and retention. 
 
All dependent variables had an association of significance with the medication 
prescribed. Figure 16 shows patients on methadone having a higher survival probability than 
those on buprenorphine for counseling adherence (Log-rank statistic = 7.374, p = .007). The 
median survival time was 41 weeks for methadone in comparison to 28 weeks for 
buprenorphine. Alternatively, buprenorphine had a higher survival probability than methadone in 
relation to opioid abstinence as seen in Figure 17 (Log-rank statistic = 22.430, p = .000), and also 
in relation to retention in treatment (Log-rank statistic = 10.921, p = .001 which is illustrated in 




Figure 16. Medication Prescribed and Counseling Adherence. This figure illustrates the Kaplan 
Meier survival curve on the association of medication prescribed and counseling adherence. 
 
 
Figure 17. Medication Prescribed and Opioid Abstinence. This figure illustrates the Kaplan 
Meier survival curve on medication prescribed and opioid abstinence. 
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Figure 18. Medication Prescribed and Retention. This figure illustrates the Kaplan Meier 
survival curve on the association of medication prescribed and retention.  
 
Multicollinearity Assumption. 
All independent variables were analyzed for multicollinearity to ensure predictor 
variables did not impact the conclusions derived from the Cox regression model. Variance 
Inflation Factors (VIFs) reveal how many times a coefficient's standard error is increased due to 
collinearity (O'brien, 2007). VIFs higher than four means collinearity does exist. Collinearity 
diagnostics were analyzed for the independent variables, all of which were below two. 
Additionally, the standard errors in the cox regression models (reported next) for all variables 
were small (Chan, 2004). Multicollinearity did not exist between the independent variables 
included in the models. 
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Cox Regression Analysis. 
To assess the relationship of personal factors and environmental influences on the 
dependent variables (counseling adherence, opioid abstinence, and retention) while controlling 
for factors such as primary drug dependence, criminal history, court-ordered treatment and 
medication prescribed, three cox regression models (one for each of the dependent variables) 
were observed. All three models were statistically significant. In the cox regression analyses 
tables (10, 11 and 12), the exponentiated coefficients (Exp B) are the hazard ratios. The hazard 
ratio describes the relationship between the covariates and survival time. It is the measure of 
effect inferred in a survival analysis (Kleinbaum & Klein, 2005). If the hazard ratio numerical 
value is less than one, with the confidence interval less than one, it means the covariate decreases 
failure (increases the likelihood of survival time). A hazard ratio of one means there is no 
relationship between the covariates and dependent variables. A hazard ratio greater than one, 
with the confidence interval above one, means the covariate has a higher risk of failure 
(decreasing the survival time). 
Counseling Adherence: In the first model, the analysis is detailed in Table 10 and the 
survival curve depicting the number of weeks patients in treatment adhered to counseling over a 
12-month period is shown in Figure 19. The model’s summary statistics indicate the model was 
strong explaining factors influencing counseling adherence as the model was statistically 
significant (x2= 48.527, p .05). 
The results indicate that age was the only significant (p.05) personal characteristic 
factor when controlling for other variables. An increase in age is associated with being more 
likely to adhere to counseling (HR=.968, 95% CI= .950-.986, p= .001).  
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For socio-economic factors, statistically significant associations were observed in relation 
to the employment and insurance variables. Patients not-in-the-workforce (i.e. student, home-
maker, disabled) (HR= 1.508, 95% CI= 1.026 - 2.218, p= .037) were more likely than those 
unemployed to not continue adhering to counseling sessions. Those without insurance (HR= 
1.000, p= .000) and public coverage (HR= .489, CI= .342 - .698, p= .000) were predictors of 
adhering to counseling. Education did not have a significant association in determining 
counseling adherence while controlling for other factors.  
The final personal factor, readiness to change, was not statistically significant. However, 
although not significant the model indicated those in action stage have a higher risk of shorter 
counseling adherence (HR= 1.476, CI= .987- 2.208, p= .058) than those in pre-contemplation.  
Neither of the environmental factors showed statistical significance while controlling for 
other factors.  
The controlling variables -criminal history, court-ordered, medication prescribed- did not 
have statistical significance with the exception of primary drug dependence. Having a primary 
drug dependence of heroin showed a higher risk of shorter counseling adherence (HR= 1.514, 
CI= 1.097 - 2.090, p= .012) than patients whose primary dependence is non-medicinal 





Cox regression predicting number of weeks adhering to counseling in treatment 
  95.0% CI  
 Exp (B) Lower Upper Sig. 
Gender 
   Male (ref) 














   White (ref) 
   Black/AA 

















Age .968 .950 .986 .001* 
Relationship Status 
   Single (ref) 
   Married 


















   Less than high school diploma(ref) 
   High school diploma/GED 
   Vocational 
   Some college 


























   Unemployed (ref) 
   Not-in workforce 
   Part-time 





















Income 1.000 1.000 1.000 .145 
Insurance 
   None (ref) 
   Public 

















Readiness to Change 
   Pre-contemplation (ref) 
   Contemplation 
   Action 






















   No (ref) 














   No (ref) 
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  95.0% CI  
 Exp (B) Lower Upper Sig. 
Drug Dependence  
   Prescription drugs (ref) 
   Heroin 
   Crack/Cocaine 
   Methamphetamine 


























   No (ref) 














   No (ref) 














   Methadone (ref) 














   -2 Log Likelihood 
   Model (x2) 
   Degrees of freedom 










Figure 19. Counseling Adherence survival curve. This figure illustrated the survival curve of 
number of weeks adhering to counseling over 12 months. 
 
Opioid Abstinence: The results for the second cox regression model analysis is described 
in Table 11, and the survival curve depicting the number of days patients abstained from opioids 
is illustrated in Figure 20. The model’s summary statistics indicate the model was strong 
explaining factors influencing opioid abstinence as the model was statistically significant (x2= 
78.961, p .05). 
No statistically significant associations were seen between personal characteristics in 
relation to opioid abstinence, while controlling for other factors; the p-values were insignificant. 
Opioid abstinence at 365 days was predicted by two socio-economic factors, employment 
and insurance. Patients with full-time employment (HR= .734, 95% CI=.544 - .991, p=.043) 
were more likely to abstain from opioids at 365 days than those unemployed. Patients receiving 
public coverage (HR= .652, 95% CI= .529 - .804, p= .000) and those with private insurance 
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(HR= .685, 95% CI= .483 - .973, p= .035) were more likely to abstain from opioids than those 
without insurance (HR= 1.000, p= .000).  
Readiness to change had surprising results when controlling for other factors. Patients in 
action phase (HR= 1.316, 95% CI= 1.028 - 1.686, p= .029), the only statistically significant 
category, were less likely to abstain from opioids at 365 days than those in pre-contemplation. 
The two environmental factors, having a support system and receiving integrated care 
were both statistically significant. Patients who reported having a support system (HR= .716, 
95% CI= .537 - .954, p= .022) at intake were more likely to abstain from opioids. Similarly, 
patients receiving integrated care (HR= .802, 95% CI= .660 - .975, p= .027) were also more 
likely to abstain from opioids at 365 days.  
The controlling variables did not have statistical significance with the exception of 
primary drug dependence. Patients with a primary drug dependence of heroin were less likely to 
abstain from opioids (HR= 1.480, 95% CI= 1.209 - 1.811, p= .000) than patients whose primary 





Cox regression, predicting number of days abstaining from opioids 
  95.0% CI  
 Exp (B) Lower Upper Sig. 
Gender 
   Male (ref) 














   White (ref) 
   Black/AA 

















Age .998 .987 1.009 .735 
Relationship Status 
   Single (ref) 
   Married 


















   Less than high school diploma(ref) 
   High school diploma/GED 
   Vocational 
   Some college 


























   Unemployed (ref) 
   Not-in workforce 
   Part-time 





















Income 1.000 1.000 1.000 .497 
Insurance 
   None (ref) 
   Public 

















Readiness to Change 
   Pre-contemplation (ref) 
   Contemplation 
   Action 






















   No (ref) 














   No (ref) 















  95.0% CI  
 Exp (B) Lower Upper Sig. 
Drug Dependence  
   Prescription drugs (ref) 
   Heroin 
   Crack/Cocaine 
   Methamphetamine 


























   No (ref) 














   No (ref) 














   Methadone (ref) 














   -2 Log Likelihood 
   Model (x2) 
   Degrees of freedom 






* Statistical significance, p  .05 
 
Figure 20. Opioid Abstinence Survival Curve. This figure illustrated the survival curve of 
number of days abstaining from opioids over 12 months. 
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Retention: the final cox regression analysis results are indicated in Table 12, and the 
survival curve depicting the number of days patients retained in treatment is illustrated in Figure 
21. The model’s summary statistics indicate the model was strong explaining factors influencing 
opioid abstinence as the model was statistically significant (x2= 144.174, p .05). 
Retention at 365 days was predicted by a number of factors, while controlling for 
patients’ primary drug dependence, criminal history, being court-ordered to treatment, and 
medication prescribed. For personal characteristics, an increase in age was associated with 
patients being more likely to still be in treatment at one year (HR= .985, 95% CI= .972 - .999, p= 
.034). Race was the other statistically significant personal characteristic. Patients under other 
(not White or African American/Black) were less likely than Whites to still be in treatment at 
365 days (HR= 1.455, 95% CI= 1.000 – 2.118, p= .050).  
For socio-economic factors, statistically significant associations were seen in all factors 
with the exception of income. Patients who had a high school diploma/GED (HR= .760, 95% 
CI= .593 - .976, p= .031) were more likely to still be in treatment at one year than those whose 
highest education level attainment was less than a diploma. Patients working part-time (HR= 
.615, 95% CI= .390 - .972, p= .037) were more likely to still be in treatment at one year than 
those unemployed (p= .028). Although not significant, the model indicated patients having full-
time employment (HR.723, p= .061) were also more likely to still be in treatment at one year 
than those unemployed. Those with insurance -public coverage (HR= .399, 95% CI= .315 - .505, 
p= .000) and private insurance (HR= .496, 95% CI= .337 - .731, p= .000)- were more likely than 
those without health insurance to still be in treatment at one year (HR= 1.000, p= .000).  
Again, readiness to change had unexpected results when controlling for other factors. 
Patients in action phase (HR= 1.454, 95% CI= 1.093 - 1.934, p= .010), the only statistically 
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significant category, were less likely to be in treatment after one year than those in pre-
contemplation. 
Having a support system did not have a significant role in determining retention. On the 
other hand, receiving integrated care (HR= .564, 95% CI= .450 - .709, p= .000) was a predictor 
of retaining in treatment.  
The controlling variables did not have statistical significance with the exception of 
primary drug dependence. Patients with a primary drug dependence of heroin were less likely to 
still be in treatment at 365 days (HR= 1.370, 95% CI= 1.086 - 1.727, p= .008) than those whose 




Cox regression, predicting number of days retained in treatment. 
  95.0% CI  
 Exp (B) Lower Upper Sig. 
Gender 
   Male (ref) 














   White (ref) 
   Black/AA 

















Age .985 .972 .999 .034* 
Relationship Status 
   Single (ref) 
   Married 


















   Less than high school diploma(ref) 
   High school Diploma/GED 
   Vocational 
   Some college 
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  95.0% CI  
 Exp (B) Lower Upper Sig. 
Employment 
   Unemployed (ref) 
   Not-in workforce 
   Part-time 





















Income 1.000 1.000 1.000 .107 
Insurance 
   None (ref) 
   Public 

















Readiness to Change 
   Pre-contemplation (ref) 
   Contemplation 
   Action 






















   No (ref) 














   No (ref) 













Drug Dependence  
   Prescription Drugs (ref) 
   Heroin 
   Crack/Cocaine 
   Methamphetamine 


























   No (ref) 














   No (ref) 














   Methadone (ref) 














   -2 Log Likelihood 
   Model (x2) 
Degrees of freedom 






* Statistical significance, p  .05 
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Figure 21. Retention Survival Curve. This figure illustrated the survival curve of number of days 
retained in treatment over 12 months. 
 
Conclusions of Hypothesis Testing 
 Each hypothesis included sub-hypotheses as it related to each of the dependent variables - 
counseling adherence, opioid abstinence, and retention in MAT.  
Personal Factors. 
 Personal characteristics. Variables in this category included: gender, race, age and 
relationship status. 
Hypothesis 1A: Gender – identification as male is negatively associated with treatment 
outcomes. 
H1ACA: Male gender is negatively associated with treatment counseling adherence.  
H1AOA: Male gender is negatively associated with abstinence from opioids. 
H1AR: Male gender is negatively associated with retention in treatment. 
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  This study divided patients into male and female categories, with males being the 
reference variable. The sample was predominantly female, with only 38.6% of male patients. 
The ANOVA revealed the means between males and females were not significantly different 
from one another as did the Kaplan Meier Method (included the mean and median, since none of 
the curves were normally distributed) for all three dependent variables. Furthermore, all three 
cox regression models were not statistically significant for gender, H1ACA, H1AOA, and H1AR 
were not supported.  
 
Hypothesis 1B: Race - identification as African American is negatively associated with treatment 
outcomes. 
H1BCA: Identification as African American is negatively associated with treatment counseling 
adherence.  
H1BOA: Identification as African American is negatively associated with abstinence from 
opioids. 
H1BR: Identification as African American is negatively associated with retention in treatment. 
The sample characteristics showed that only a small percentage (4.5%) of patients were 
African American/Black. The bivariate associations between race and counseling adherence, 
opioid abstinence, and retention were all statistically insignificant. The cox regression analyses 
were also statistically insignificant with the exception of patients in the other category being less 




Hypothesis 1C: Age is positively associated with treatment outcomes. 
H1CCA: Age is positively associated with treatment counseling adherence.  
H1COA: Age is positively associated with abstinence from opioids. 
H1CR: Age is positively associated with retention in treatment. 
Bivariate associations between age and each treatment outcome were all statistically non-
significant. However, when controlling for additional factors, an increase in age is associated 
with being more likely to adhere to counseling at one year. This variable was a statistically 
significant predictor. Age was not significant in the opioid abstinence model. For the retention 
model, the association was statistically significant, showing an increase in age was associated 
with being more likely to retain in treatment at one year. Therefore, H1CCA and H1CR were 
supported, and H1COA was not supported. 
 
Hypothesis 1D: Single relationship status is positively associated with treatment outcomes. 
H1DCA: Single - relationship status is positively associated with treatment counseling adherence.  
H1DOA: Single - relationship status is positively associated with abstinence from opioids. 
H1DR: Single - relationship status is positively associated with retention in treatment. 
Bivariate analyses did not indicate any statistically significant associations with 
relationship status. The cox regression analyses were also all not statistically significant. H1DCA, 
H1DOA, and H1DR were not supported. 
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Hypothesis 2A: Higher education is positively associated with successful treatment outcomes in 
MAT patients.  
H2ACA: Higher education is positively associated with treatment counseling adherence.  
H2AOA: Higher education is positively associated with abstinence from opioids. 
H2AR: Higher education is positively associated with retention in treatment. 
The ANOVA analyses did not demonstrate any statistically significant difference in 
means between the education groups in each of the time dependent variables, as well as the chi-
square analyses in the Kaplan Meier model. The likelihood of still being retained in treatment 
differed across education levels, and most of the cox regression analyses also showed no 
statistically significant association between education and the dependent variables. The retention 
analysis however, did have a significant relationship between patients with a high school 
diploma/GED being more likely to be retained in treatment at one year. However, no 
significance was indicated with an increase in education, therefore H2ACA, H2AOA, and H2AR 
were all not supported. 
 
Hypothesis 2B: Employment is positively associated with successful treatment outcomes in 
MAT patients.  
H2BCA: Employment is positively associated with treatment counseling adherence.  
H2BOA: Employment is positively associated with abstinence from opioids. 
H2BR: Employment is positively associated with retention in treatment. 
 Two ANOVA analyses did not demonstrate any statistically significant difference in 
means between the employment groups for the counseling adherence and retention dependent 
variables. There was a statistically significant difference between the unemployment and full-
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time employment means in the opioid abstinence ANOVA. Additionally, the cox regression 
analysis also had a statistically significant association of patients with full-time employment 
being more likely to abstain from opioids at 365 days than those unemployed. In the counseling 
adherence cox regression analysis unemployed and not-in-the-work force had significant 
associations, with those not-in-the-workforce less likely than those unemployed to be in 
counseling at one year. The retention cox regression showed patients who worked part-time were 
more likely to still be in treatment at one year than those unemployed. H2BCA is therefore not 
supported, whereas H2BOA is supported for full-time employment, and H2BR is supported for 
part-time employment.  
 
Hypothesis 2C: Having a higher income is positively associated with successful treatment 
outcomes in MAT patients.  
H2CCA: Higher income is positively associated with treatment counseling adherence.  
H2COA: Higher income is positively associated with abstinence from opioids. 
H2CR: Higher income is positively associated with retention in treatment. 
Correlations revealed no significant associations between income and any of the 
dependent variables. The three cox regression analyses also revealed no significant associations 
with income, H2CCA, H2COA, and H2CR were not supported. 
 
Hypothesis 2D: Having health insurance is positively associated with successful treatment 
outcomes in MAT patients.  
H2DCA: Having health insurance is positively associated with treatment counseling adherence.  
H2DOA: Having health insurance is positively associated with abstinence from opioids. 
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H2DR1: Having health insurance is positively associated with retention in treatment. 
H2DR2: Having public insurance (Medicaid) is positively associated with retention in treatment. 
Bivariate analyses -both ANOVA and Kaplan Meier survival curves- illustrated 
statistically significant associations between insurance and treatment outcomes. When 
controlling for additional variables in the cox regression analyses the associations were also 
statistically significant. Only public insurance (not private) did show a statistical significance 
with counseling adherence; patients being more likely to still be in counseling at one year than 
those without insurance. Both insurance groups did indicate being more likely to abstain from 
opioids and retained in treatment at one year. All four hypotheses were supported H2DCA, 
H2DOA, and H2DR, and H2DR2. H2DCA was supported only for public insurance.  
 
Hypothesis 3A: Readiness to change is positively associated with treatment outcomes in MAT 
patients.  
H3ACA: Readiness to change is positively associated with treatment counseling adherence.  
H3AOA: Readiness to change is positively associated with abstinence from opioids. 
H3AR: Readiness to change is positively associated with retention in treatment. 
 None of the bivariate analyses had statistically significant associations between the 
readiness to change categories and dependent variables. The cox regression opioid abstinence 
and retention models did show significance for the action category, but in the opposite direction. 
Patients in the action phase were less likely to abstain from opioids and still be in treatment at 
one year. None of the other categories showed significant results, H3ACA, H3AOA, and H3AR 
were not supported. 
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Environmental Influences. 
Hypothesis 4A: Having social support during treatment is positively associated with treatment 
outcomes in MAT patients. 
H4ACA: Having social support is positively associated with treatment counseling adherence.  
H4AOA: Having social support is positively associated with abstinence from opioids. 
H4AR: Having social support is positively associated with retention in treatment. 
 All counseling adherence analyses -ANOVA, Kaplan Meier, and Cox regression- were 
all not statistically significant. Conversely, all opioid abstinence models were statistically 
significant indicating patients reporting social support at intake were more likely to abstain from 
opioids at one year. Retention models were statistically significant with bivariate relationships, 
but insignificant when controlling for other factors in the cox model. H4ACA and H4AR were not 
supported, whereas H4AOA was supported.  
 
Hypothesis 5A: Patients receiving integrated care are associated with positive treatment 
outcomes in MAT. 
H5ACA: Receiving integrated care is positively associated with treatment counseling adherence. 
H5AOA: Receiving integrated care is positively associated with opioid abstinence. 
H5AR: Receiving integrated care is positively associated with retention in treatment. 
 All bivariate analyses were statistically significant. However, when controlling for other 
factors, there was no statistically significant association with counseling adherence. In regard to 
the other two dependent variables, patients receiving integrated care were more likely to abstain 
from opioids and retain in treatment at one year. Therefore, H5AOA and H5AR were supported, 
and H5ACA was not supported. 
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 Table 13 provides a Hypothesis Testing Summary of the above section, which 
demonstrates whether a hypothesis was supported or not, indicated by an “X” as a result of the 




Hypothesis Testing Summary  
Hypothesis Supported Not 
Supported 
H1ACA: Male gender is negatively associated with treatment 
counseling adherence.  
 X 
H1AOA: Male gender is negatively associated with abstinence from 
opioids. 
 X 
H1AR: Male gender is negatively associated with retention in 
treatment 
 X 
H1BCA: Identification as African American is negatively associated 
with treatment counseling adherence.  
 X 
H1BOA: Identification as African American is negatively associated 
with abstinence from opioids. 
 X 
H1BR: Identification as African American is negatively associated 
with retention in treatment. 
 X 
H1CCA: Age is positively associated with treatment counseling 
adherence.  
X  
H1COA: Age is positively associated with abstinence from opioids.  X 
H1CR: Age is positively associated with retention in treatment. X  
H1DCA: Single - relationship status is positively associated with 
treatment counseling adherence.  
 X 
H1DOA: Single - relationship status is positively associated with 
abstinence from opioids. 
 X 
H1DR: Single - relationship status is positively associated with 
retention in treatment. 
 X 
H2ACA: Higher education is positively associated with treatment 
counseling adherence.  
 X 
H2AOA: Higher education is positively associated with abstinence 
from opioids. 
 X 
H2AR: Higher education is positively associated with retention in 
treatment. 
 X 
H2BCA: Employment is positively associated with treatment 
counseling adherence.  
 X 
H2BOA: Employment is positively associated with abstinence from 
opioids. 
X (ft) X (pt) 
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Hypothesis Supported Not 
Supported 
H2BR: Employment is positively associated with retention in 
treatment. 
X (pt) X (ft) 
H2CCA: Higher income is positively associated with treatment 
counseling adherence.  
 X 
H2COA: Higher income is positively associated with abstinence from 
opioids. 
 X 
H2CR: Higher income is positively associated with retention in 
treatment. 
 X 
H2DCA: Having health insurance is positively associated with 




H2DOA: Having health insurance is positively associated with 
abstinence from opioids. 
X  
H2DR1: Having health insurance is positively associated with 
retention in treatment. 
X  
H2DR2: Having public insurance is positively associated with 
retention in treatment. 
X  
H3ACA: Readiness to change is positively associated with treatment 
counseling adherence.  
 X 
H3AOA: Readiness to change is positively associated with abstinence 
from opioids. 
 X 
H3AR: Readiness to change is positively associated with retention in 
treatment. 
 X 
H4ACA: Having social support is positively associated with treatment 
counseling adherence.  
 X 
H4AOA: Having social support is positively associated with 
abstinence from opioids. 
X  
H4AR: Having social support is positively associated with retention 
in treatment. 
 X 
H5ACA: Receiving integrated care is positively associated with 
treatment counseling adherence. 
 X 
H5AOA: Receiving integrated care is positively associated with 
opioid abstinence. 
X  
H5AR: Receiving integrated care is positively associated with 




CHAPTER FIVE: DISCUSSION 
Discussion of Findings 
 The aim of the study was to examine characteristics and factors associated with 
counseling adherence, opioid abstinence, and retention in patients receiving MAT for up to one 
year. The study focused on these three key areas because successful patient engagement in 
treatment decreases drug use, and most importantly, mortality.  
Personal Factors. 
Personal Characteristics: The results of this study indicated that for personal 
characteristics, gender, race and relationship status was not a significant factor associated with 
counseling adherence, opioid abstinence or retention. These findings were supported in the 
literature (Darker et al., 2016; Deck & Carlson, 2005; Banta-Green et al., 2009; Wasserman et 
al., 2011). Age was the only personal characteristic which played a statistically significant role 
when controlling for other factors in counseling adherence and retention in treatment. This was 
consistent with research studies indicating an increase in age as a predictor of retention (Deck & 
Carlson, 2005; Banta-Green et al., 2009; Wasserman et al., 2011; Darker et al., 2016; Joe et al., 
1998; Proctor et al, 2015). This is an important factor for clinicians to be mindful of. Especially 
with the opioid epidemic shift to a younger population, treatment agencies may benefit from 
utilizing evidence-based practices for adolescents and young adults to better engage and retain 
the younger population in treatment. 
Socio-economic Factors: Prior literature has shown a direct correlation between social 
determinants of health, inclusive of socio-economic factors and health outcomes. Limited studies 
however, have researched the influence of socio-economic factors influence on MAT outcomes 
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(Darker et al., 2016; Rash, Andrade & Petry, 2013; Rash, Olmstead & Petry, 2009). This study 
found there was no association with higher levels of education and counseling adherence, and 
opioid abstinence. However, having lower education (patients with a high school diploma or 
GED) was associated with retention. This is consistent with a study that found higher education 
was not associated with retention in treatment (Darker et al., 2016). In terms of employment, 
patients working part-time were more likely to be retained in treatment at one year. Those 
working full-time were more likely to abstain from opioids. This is not surprising since many 
jobs have Drug and Alcohol Policies which employees are required to adhere to as part of their 
employment (Hartwell, Steele, French, & Rodman, 1996). O’Connell, Enev, Martin and Inciardi 
(2007) also assert having employment instills a renewed sense of self- identity and benefits of 
not using substances (p. 1093). A limitation of the study, which is discussed further below, is 
this information was collected at intake. This also correlates with the income variable which had 
all non-significant associations.  
Health insurance had the most impactful association with the variables studied. In the 
initial model, only public insurance (Medicaid, federal and state funding coverage) showed 
statistical significance for adhering to counseling at one year. The associations were statistically 
significant and had the lowest hazard ratios for the opioid abstinence and retention models. 
Findings agree with Deck and Carlson (2005) and Banta-Green et al. (2009) who reported that 
patients with public assistance funding were more likely to stay in treatment. This is a significant 
factor as the epidemic has now received national attention. In the US President’s 2017 Public 
Health Emergency declaration of the national crisis, allocating additional funding to treatment 
was not included. Action for telemedicine, improving hiring process for addiction specialist, 
dislocated worker grants and shift in HIV resources for those also affected by substance use were 
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the focal areas of the declaration (The White House, United States Government, 2017). Although 
this was an important step in the right direction, more is needed than just acknowledging the 
epidemic, which has been an issue for quite some time. Funding to increase access to and 
engagement in treatment was considerably missing from the declaration. Florida’s governor and 
political leaders however, announced support for legislation towards public assistance funding 
for the opioid crisis (Wilson, 2017). This is expected to pass during this year’s Florida legislative 
session.  
Readiness to change: This was not an influential factor in any treatment outcome, which 
did not support the literature. A few studies indicated that treatment motivation was an important 
factor in treatment success, with motivated patients more likely to abstain from opioids and stay 
in treatment (Harrell et al., 2013; Kelly et al., 2011; Pantalon et al., 2002). Surprisingly, the 
action phase (HR= 1.316) was statistically significant in the reverse direction, implying patients 
were less likely to abstain from opioids at 365 days than those in the pre-contemplation phase. 
This variable was assessed by the admissions counselor at intake; it would be interesting to see if 
patients are in different phases during their treatment plan updates and if this had any effect on 
the survival times. 
Environmental Influences. 
In examining the environmental factors both revealed significant associations.  
Social Support: When controlling for other variables in the cox regression, only the 
opioid abstinence models were significant, suggesting those with a support system were more 
likely to abstain from opioids. This was consistent with two studies (Cavaiola et al. 2015; 
Franckowiak & Glick, 2015) but was inconsistent with the Wasserman et al. (2001) article. 
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These results suggest that addiction counselors can help patients abstain from opioids by 
encouraging them to add positive support during treatment through group sessions or 12-step 
programs. 
Integrated care: All bivariate associations indicated positive associations with treatment 
outcomes. In the cox regression, patients receiving integrated care were more likely to abstain 
from opioids and retain in treatment (counseling adherence was not significant). As indicated in 
the literature, integrated care improves patient-centered care and cost-effectiveness (Kelly et al., 
2011; Farber et al., 2012; HHS 2016). The Surgeon General’s 2016 report indicated both the 
substance use and general health care workforces are undertrained to meet this need. “Health 
care now requires a new, larger, more diverse workforce with the skills to prevent, identify, and 
treat substance use disorders, providing “personalized care” through integrated care delivery” 
(HHS, 2016, p.6-2). Additionally, health care and treatment agencies will need funding to not 
only provide integrated treatment teams, but integrated services to meet patients’ needs.  
Controls. 
An analysis of the control variables revealed patients whose primary drug dependence 
was heroin, were less likely to adhere to counseling, abstain from opioids, and retain in treatment 
at one year than patients with a primary dependence of prescription drugs. The association to 
opioid abstinence was consistent with the findings of Moore et al. (2007) but conflicted with 
Banta-Green et al. (2009) in regard to retention. This population may require additional attention. 
Counseling staff and treatment teams should utilize evidence-based curriculum, and work on 
developing initiatives to further engage this population. Bivariate analysis revealed significant 
associations with the medications used. Those on methadone were more likely to adhere to 
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counseling sessions, whereas patients taking buprenorphine were more likely to abstain from 
opioids and still be in treatment at one year. This may also directly correlate to available funding 
(buprenorphine is costlier) and health coverage.  
The study’s results were slightly different from the conceptual model in some respects. 
With the guidance of the conceptual model, personal factors such as age, and insurance, in 
addition to the environmental factors of social support and integrated care, were predictors to 
counseling adherence, opioid abstinence, and retention in MAT. Though the concepts in the 
models were interwoven, some personal factors -demographics, socio-economic and readiness to 
change- showed no statistical significance to the treatment outcomes. The findings from the self-
efficacy and readiness to change constructs were inconsistent with the literature. Nevertheless, 
the conceptual model did appear to address the dynamic relation between personal factors or 
environmental influences and behavior in certain instances. The outcome expectancies domain 
from the social cognitive theory, in addition to the behavioral and normative constructs from the 
theory of reasoned action. 
Limitations 
 Several study limitations should be noted. The original use of the data were not for 
research purposes. Therefore, variables such as support systems did not have additional 
information to further identify the type of support, for example, whether it was a spouse, relative, 
or friend. Additionally, the severity of patient’s addiction was not controlled for. 
Though usage of data from clinical records has strengths, it also has limitations. Missing 
data are a major limitation of using existing clinical records (Jacobsen, 2017). The assumption 
cannot be made that the health record includes a full picture of each patient’s characteristics and 
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treatment episode (Jacobsen, 2017, p. 164). Whether the missing data were patients lost to follow-up, 
patients transferring, or staff’s inability to completely enter information into the clinical record; 
statistical methods were employed to control for this. Survival analysis not only focuses on the time 
variable, it censors data, whether missing, lost to follow-up, death or patients not accounted for 
during the treatment timeframe. 
 Also, the measures may not have been completely reliable or valid. Many of the 
independent variables were collected upon admission and could have changed over the year in 
which the study measured the survival of the patient. Future studies should include a feasible 
follow-up period to evaluate any changes in patient’s status, for instance the education level, 
income, support systems, since stabilizing in treatment. Additionally, the initial intake 
assessment relies on self-report for some questions. Patients’ recall of factors such as criminal 
history, education level, income, and support system may be biased. 
Finally, in observational studies, unlike experimental studies, findings may suggest, but 
do not determine, a causal pathway. Variables that affected the findings that are not included in 
the analysis may have biased the results (omitted variable bias) (Carlson & Morrison, 2009). 
Strengths & Generalizability 
The generalizability of the research study should be carefully considered as the data were 
from a single city in Florida. The most recent demographics for Florida from SAMSHA’s 
Treatment Episode Data Sets (TEDS) for opioid dependent admissions is 2013. Florida is one of 
over 20 states which more recent information is not available. Although comparable for age and 
race, gender shows almost the reverse of the percentages usually encountered, with the majority 
of opioid dependents being male in the TEDS data. However, in general this statistic is shifting 
nationally (Banta-Green et al., 2009). Additionally, the patients in the sample received treatment 
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at a not-for-profit MAT facility, and as the sample characteristics illustrated, included mostly 
low-income persons, of which a good portion received public assistance. Therefore, these 
findings may not be generalizable to the entire population. 
Despite the limitations listed above, retrospective cohort designs using clinical records 
also have strengths. Neither the patient nor services provided by the treatment agency was 
influenced by being included in the study. Furthermore, use of data from clinical records 
eliminates the need for additional required resources, essentially time and money, in the 
collection of primary data (Song, & Chung, 2010). Clinical records from a large behavioral 
agency provided the advantage of a large sample size and detailed data that would not have 
otherwise been feasible.  
The study extends the literature, as few studies have examined retention with a large 
sample size in MATs using cox regression analysis (Hser et al., 2013). This study goes beyond 
prior research in also studying counseling adherence and opioid abstinence as outcome variables, 
instead of solely focusing on retention. Since methadone was the only accepted treatment for 
opioid abstinence for a long time, few studies have also included buprenorphine patients. 
Additionally, the sample included a large percentage of those whose primary drug dependence 
was non-medicinal prescription drugs.  
Lastly, the study addresses a very timely issue, as the opioid epidemic was responsible 
for more than 42,000 deaths in the US in 2016 (CDC, 2017). Understanding factors influencing 
treatment outcomes assists the substance use disorder workforce when assessing and engaging 
patients in treatment. Equally important, it provides policy and lawmakers with data showing the 




Given the current opioid epidemic in the United States, particularly in the state of Florida 
where the study sample is from, this study has significant implications for policies, such as 
legislative initiatives, and programs, such as effective treatment modalities and MAT expansions. 
The following sections discuss some of these policy and programmatic implications.   
Policy Implications. 
In 2016, Florida had over 5,725 opioid-related deaths (a 35% increase from the prior 
year), yet the state does not have an office tracking the epidemic (Duran, 2018). Governor Scott 
in 2009 eliminated The Office of Drug Control (Duran, 2018). Such an agency needs to be at the 
forefront of the epidemic, to utilize collaborative teams to assess, treat, and prevent the crisis. 
Studies such as this would provide viable information to a centralized office working on the 
epidemic in the State.  
The 2018 Florida Legislative session introduced House Bill 1025 to reinstate the Office 
of Drug Control. The bill lists a number of responsibilities of the agency inclusive of monitoring 
state policies and data (including overdoses) related to substance use, developing a strategic plan 
to reduce substance use within the State, working with the behavioral health managing entities 
throughout the state for resources and advocacy, conducting media campaigns on the negative 
effects of substance use and making policy recommendations (Florida House of Representatives, 
2018). However, the bill was indefinitely postponed and withdrawn from consideration. Having 
a central agency to establish an assessment of the State’s needs and create a comprehensive plan 
to overcome the epidemic should be reconsidered for the next session. An additional 
recommendation in the policy would be to assess the opioid addiction treatment workforce in the 
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State and the collaborative efforts of treatments agencies providing integrated care. The study 
highlighted patients receiving integrated care were more likely to abstain from opioids and retain 
in treatment. The US Surgeon General in the Facing Addiction in America Report highlighted 
the importance of integrated care systems in healthcare (HHS, 2016). Furthermore, calling to 
attention the need to workforce needs – “Well-supported evidence shows that the current 
substance use disorder workforce does not have the capacity to meet the existing need for 
integrated health care, and the current general health care workforce is undertrained to deal with 
substance use related problems” (HHS, 2016, p. 6-2).  
The availability of funding/coverage to pay for treatment services was a key factor for 
patients’ survival time in MAT. The study indicated in each of the cox regression models that the 
availability of health insurance coverage to pay for treatment was significant. Self-pay patients 
without private insurance or public funding were less likely adhere to counseling, abstain from 
opioids and retain in treatment. This is of importance, as the US President in October 2017 
declared a Nationwide “Public Health Emergency” to address the opioid epidemic but fell short 
of requesting funds for treatment. Florida’s Governor recently announced proposing $50 million 
($27 million from federal funds) in the budget towards combating the opioid epidemic, which 
will be important during this legislative session (Office of Governor Rick Scott, 2017). Adequate 
funding is necessary for successful treatment outcomes. State legislators initially planned to 
request an additional $25 million for treatment, however the recent events in Florida, became 
more of a priority for resources towards gun control (Mower, 2018). Florida’s recent budget 
proposal (HB 5001: General Appropriations Act) includes $704 million to community substance 
and mental health services ($19 million decrease from the prior year) (Florida Senate, 2018). The 
appropriations act often includes non-reoccurring funds, with the exception of a few member 
 101 
projects, special projects or populations, for instance women special funding (pregnant, post-
partum and their affected families), family intensive treatment, funding for specific treatment 
agencies and Sheriff Office’s (Florida Department of Children and Families, 2018). With the 
current opioid epidemic in the state, and the study illustrating the funding need for a higher 
probability a recommendation of reoccurring funds specifically for Medication Assisted 
treatment programs would be ideal.  
House Bill 1025 also includes a request for a Medicaid waiver. Florida is one of nineteen 
states, which did not expand Medicaid under the Affordable Care Act (ACA), which leaves just 
under half a million people in the coverage gap (Norris, 2017). The Agency for Health Care 
Administration can request federal approval for treatment (inclusive of MAT) to support services 
that Medicaid does not cover without the waiver to improve access and quality of services 
thereby assisting to restore the care continuum (Florida House of Representatives, 2018, p. 4) 
In terms of federal policy, repealing the Affordable Care Legislation will have 
detrimental effects to this population (Bailey, 2017; Zezima & Ingraham, 2017). The study 
illustrated the importance of public funding, of which a larger majority of the patients was on 
Medicaid. It is estimated that under an ACA repeal, over 2.8 million people with a substance use 
disorder (220,000 with an opioid disorder) could lose health care coverage (Bailey, 2017, para. 
3). Throughout the nation, and in the State of Florida, the need remains high for opioid addiction 
treatment. A reduction in coverage will create an adverse effect in combating the epidemic.  
Program Implications. 
Age was the only personal factor statistically significant when controlling for other 
factors in counseling adherence, and treatment retention. Proctor et al. (2015) asserts younger 
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patients’ maturity levels and understanding of negative consequences of substance use may cause 
less success in treatment outcomes. Efforts to increase engagement of younger adults in 
treatment adherence, by utilizing evidence-based models focused on young adults or adolescents, 
to retain them in treatment is warranted. Focusing on early intervention treatment techniques -
integrating motivational enhancement, and therapeutic groups based on age- could also be 
beneficial for the younger patients (Proctor et al., 2015).  
Treatment providers should also highly encourage family/support groups or require 12-
Step Programs (Methadone Anonymous) to increase social support. The study indicated those 
with a support system were more likely to abstain from opioids. Cavaiola et al. (2015) findings 
indicated patients were appreciative of a number of different factors from the support systems. 
Therapeutic support groups could be beneficial in helping the family/support system understand 
how to express belief/confidence in their recovery, being honest, refraining from being critical 
and expressing concern (Cavaiola et al., 2015, p. 190).  
Providing patient-centered care, inclusive of integrated care services, is also a 
collaborative effort that requires resources for training, services, and staff. Also, from a clinical 
standpoint, resources should also be allocated to the treatment of heroin (not just opioids in 
general). Patients with a heroin primary drug dependence were less likely to adhere to 
counseling, abstain from opioids, and retain in treatment than those with a primary drug 
dependence of prescription drugs.  
From the context of health and public affairs, it is essential that policymakers, health care 
professionals and researchers work collectively to ensure that public funding is allocated to MAT 
programs, to ensure continuation in treatment. Efforts to increase funding for opioid abuse 
treatment and additional research for evidence-based interventions for heroin and non-medicinal 
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prescription drug interventions are needed. Also utilizing an interdisciplinary approach to 
support integrative care services being provided throughout MATs. The overall benefits of 
treatment and factors that increase survival for more than a year will enable citizens to be 
positive and productive. 
Future Research 
While this was an important study on the association of personal and environmental 
factors and treatment outcomes, additional research is needed to address the current opioid 
climate. First, unfortunately patients on vivitrol did not have their clinical information in the 
EHR and could therefore not be included in the study. Having a study inclusive of patients on 
vivitrol is important, as there is not much literature on this medication in regard to survival 
analysis in MAT. Comparative effectiveness studies need to be conducted to see if there are 
differences between patients on this medication in comparison to others. Unlike with methadone 
and buprenorphine, patients are required to have that initial detoxification period prior (seven to 
ten days minimum) and can take the medication via injection or orally once per month (instead 
of daily). 
As this study suggests, personal factors do not play a large role in treatment outcomes 
whereas the treatment environment and social support do; it is also important to study the context 
of the treatment environment and patients’ social context. For example, quantitative studies 
should be conducted that: examine close relationships that may increase the risk of opioid use; 
define the settings in which social relationships occur; and explore the social and cultural norms 
in relation to opioid abuse and treatment. Qualitative studies could explore the contextual and 
environmental issues in detail. Such qualitative and quantitative studies could address the 
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personal factors and environmental influences linkage that was not studied in the triangular 
conceptual model utilized in this study (see Figure 8). 
Additionally, subsequent research should assess the needs of substance use agencies to 
provide integrated care. This is imperative to improve care coordination, and financial costs to 
both the patients and providers, and an area, which the US Surgeon General said both the health 
and substance use workforce are lacking the capacity to meet the needs of an integrative care 
system (HHS, 2016; Stone & Katz, 1996). In addition, research is needed to examine the 
knowledge and beliefs of patient-centered integrated care with the addiction and health 
workforces to be able to develop necessary trainings to engage more patients in integrated care. 
Finally, it will be intriguing to understand how the cost of medications and treatment 
coverage compare across private insurance providers. Whether insurance companies limit the 
length of time patients are able to receive services, or medications received -methadone, 
buprenorphine, or vivitrol. Furthermore, with the increase in primary-care providers treating this 
population, it will also be beneficial to examine treatment outcomes in the primary care 
outpatient office setting in comparison to MATs. 
Conclusion 
 The objective of this study was to determine if treatment outcomes, measured by 
counseling adherence, opioid abstinence, and retention, were influenced by personal 
characteristics, socio-economic factors, readiness to change, social support and integrated care. 
Guided by a conceptual framework inclusive of social cognitive theory, transtheoretical model, 
and theory of reasoned action; a retrospective cohort design was conducted. Bivariate analyses 
and three cox regression models revealed factors associated with positive treatment outcomes.  
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This dissertation expands the literature and contributes to the knowledge of 
characteristics and factors associated with MAT outcomes. MAT is a pivotal step in preventing 
relapse and reducing opioid mortality. The study provides crucial information on the need for 
funding to support patients’ continual efforts to engage in treatment. As the opioid epidemic has 
become a national public health concern, having treatment interventions inclusive of support 
systems and integrated care in addition to the availability of funding for treatment is of uttermost 









Table 14. Prior Medication Assisted Treatment Studies  
Author & Pub. Year Title Type of Study Focus Critical Findings 
Banta-Green et al., 
2009 
Retention in methadone 
maintenance drug 
treatment for prescription-
type opioid primary users 







Sample: heroin and 
prescription drug users 
receiving MMT in WA.   
(n = 2308 
Assess retention in 
treatment for opioid 
dependent prescription 
drug users in 
comparison to heroin 
users 
Not adjusting for other 
factors, odds of retention 
for PDU was 1.33 (95% 
CI, 1.03, 1.71). 
Odds of retention for 
PDU in comparison to 
heroin users: 1.25 (95% 
CI, 0.93, 1.67). No 
statistical difference in 
treatment type when 
adjusting for tx 
agencies, public 
assistance type, services 
– medical, psychiatric, 
legal, familial, and 
demographics 
Saxon et al., 2013 Medication-assisted 










(n = 1269) 
Summarizes clinical 




treatment for opioid use 
disorder 
Better tx retention for 
methadone. 
Decrease illicit opioid 
use early in tx with 
buprenorphine. 
Risk behavior (injection 
drug use) decline14.4 to 
2.4% for buprenorphine 
and 14.1 to 4.8% for 







Author & Pub. Year Title Type of Study Focus Critical Findings 
Kresina & Lubran, 
2011 
Improving Public Health 
Through Access to and 
Utilization of Medication 
Assisted Treatment 
 
Theoretical Providing integrated 
care and improving 
care coordination for 
access to and utilization 
of Medication Assisted 
Treatment 
 Integrated Models of 
MAT 
Coordination Care 
Models for MAT 
Darker at al., 2016 Demographic and clinical 
factors predicting 
retention in methadone 
maintenance: results from 
an Irish cohort 
 






receiving MMT in 
Ireland 
(n= 189) 
To explore the 
demographic and 
clinical factors 





patients who had fewer 
breaks in tx: single, 
older, living in their own 
home, medication – 
higher methadone dose 
or taking antipsychotic 
meds 
Factors enabling regular 
attendance at MMT:  
Sobriety (37.5 %), to 
avoid withdrawals 
(16.1 %), methadone 
dependence (13.9 %) 













Author & Pub. Year Title Type of Study Focus Critical Findings 
Moore et al., 2007 Primary Care Office-
based Buprenorphine 
Treatment: Comparison 















characteristics and tx 
outcomes of heroin and 






outcomes over heroin 
dependents. 
POD characteristics: 
younger, less opioid use, 
more likely to be white, 
with higher earning 
incomes 
POD vs heroin patients: 
completing treatment: 
59% vs. 30%. 
Length of stay: 21.0 vs. 
14.2 weeks 
Rate of negative US 
56.3% vs. 39.8%, 
 all p values < .05. 
Timko et al., 2016 Retention in medication-
assisted treatment for 








Sample: 55 articles 
between 2010 - 2014 
Reviewing literature on 
retention in medication 
assisted treatment. 
Retention rates varied 
from 3 months to over a 
year. 
Retention rates were 
highest in 
buprenorphine/naloxone.  
1 study measured 
retention in treatment 
over a year. 
Studies with larger 
samples and longer-term 




Author & Pub. Year Title Type of Study Focus Critical Findings 
Franckowiak & Glick, 
2015 















self-efficacy and tx 




Average increase in 
general GSE scores:  5.1 
points, when comparing 
pre and post-test at a 
95% CI. Total scores 
increased an average of 
10.1 points. P< .01 
 
There was no correlation 
between negative drug 
screens and self –
efficacy. 
 
There was no correlation 
with number of 
counseling sessions and 
self –efficacy. 
Zhang et al., 2003 Does retention matter? 
Treatment duration and 







Sample: 62 drug 
treatment units, 4005 
patients  
To examine a 
relationship (minimum 
threshold, continuous 
or non-linear) between 
treatment duration and 
drug use improvement 
Positive linear 
relationship with 
duration in treatment, 
and drug use 
improvement for MMT 
 
Retention in outpatient 
(non-MMT and long-




Author & Pub. Year Title Type of Study Focus Critical Findings 
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Hubbard et al., 2003 Overview of 5-year 
follow-up outcomes in the 






Analysis: paired t-test, 
logistic regression 
 
Sample: 1,393 patients 
from 96 treatment 
programs  
To describe and 
examine the association 
between treatment 
duration and modalities 
– outpatient methadone, 
outpatient, short term 
inpatient, and long term 
residential 
Duration of 6 months or 
greater in treatment was 
associated with 
decreased criminal 
activity and full-time 
employment increase  
Kelly et al., 2011 Predictors of methadone 
treatment retention from a 










sample, 361 MMT 
patients 
Examining predictors 
of three domains – 
personal, program and 
community factors – 





predictors: being female, 
higher treatment 
readiness at admission 
(p = .005); but lower 
desire for help, (p = 
.010).  
 
1-year retention: higher 
medical and lower legal 
composite scores; in 
addition to higher 











Table 15. Theoretical Approaches Literature Review Summary 
Author & 
Pub. Year 
Title Theory Type of Study/ 
Unit of Analysis 
Focus Critical Findings 
Gullo et al., 
2017 
Social cognitive 
predictors of treatment 


















Abstinence increased with tx 
sessions (1.20x more likely). 
Negative expectancies 
increased the odds of 
abstinence, as was emotional 
relief refusal. 
Emotional relief refusal self-
efficacy predictor of improved 
treatment outcomes; and was 





analysis of substance 




Theoretical Analysis of SU Self-efficacy beliefs create 
desired changes 
Guides: 
Assessment of self-efficacy 
Enabling community (for 
negative drug use) 





efficacy is efficacious: 
toward an addicted-
self model of cessation 














Predictors: low controlled use 
of self-efficacy was a predictor 
of abstinence acceptance. 
Increasing levels of abstinence 
acceptance was associated with 
drug abstinence. 
An increase in abstinence 
acceptance was associated with 






Title Theory Type of Study/ 
Unit of Analysis 
Focus Critical Findings 
Dijkstra et 
al., 2006 
Is social cognitive 





  At the 2-month follow-up, the 
matched interventions were 
significantly more effective in 












Theoretical Application of 




Various substance abuse 
studies presented on the theory 
1983 – 2004.  




Motivation to change 
and readiness for 
counseling in 
prescription-drug-





















Majority of the population was 
in pre-contemplation stage, 
followed by contemplation 
stage.  
Self-efficacy to change was 
associated with readiness to 
change. 
Receiving counseling was also 
rated positive  
Harrell et al., 
2013 
A latent class 
approach to treatment 
readiness corresponds 
to a transtheoretical 















significantly more likely to test 
for marijuana, whereas the 
action phase was significantly 









Title Theory Type of Study/ 
Unit of Analysis 
Focus Critical Findings 
Pantalon et 
al., 2002 
The URICA as a 
measure of motivation 
to change among 
treatment-seeking 
individuals with 
















Committed action: significantly 
higher percentage of abstinent 
days in comparison to lower 





model of health 
behavior 
Transtheoretical Theoretical Providing an 
understanding of 
the constructs 
and stages of 
change 
Identifying the core constructs: 
stages of change, processes of 
change, decisional balance, 
self-efficacy, temptation 
Assumptions: complexities of 
behavioral change require more 
than a single theory, behavior 
change is a process, planned 
intervention is required for 
behaviors change in the 
population, at-risk populations 
are usually not prepared for 
action, specific 
interventions/process need to 
occur at identified stages for 
progress to occur, and chronic 
behavior patterns are usually a 
result of biological, social and 
self-control 





Title Theory Type of Study/ 
Unit of Analysis 









treatment: A test of the 
theories of reasoned 











Examine if TRA 




patients to use 
MAT 
Confirms TRA application as a 
conceptual model for 
explaining attitudes and 
intentions (counselor’s) and 
linkage of social norms. SEM 
showed significant relation b/w 
intentions & behavior, attitudes 






























TRA/TPB was the most 
effective in predicting use of 
treatment programs.  
Hierarchical MR: Being 
homeless was the only socio-
demographic variable found to 
significantly predict tx at the 
1st stage. On the 2nd stage: 
being on parole and using 
drugs regularly for fewer than 
20 years were also predictors 
with homelessness.  
Treatment utilization is 
predicted by behavioral beliefs 
favoring treatment and self-








Title Theory Type of Study/ 
Unit of Analysis 




A comparison of the 
Theory of Planned 
Behavior and the 






















identified by the 
subjects 
Inclusion of behavioral control 
is an indicator of practice and 
intention. 
Effects of perceived behavior 
control are most telling when 
the behavior presents a problem 
with control.  
Rich et al., 
2015 
Theory of planned 
behavior and 













Explained 33% of variance in 
intention and 9% in adherence 
behavior. 
Results support theory 






An examination of the 
Individual-Difference 
Approach to the Role 
of Norms in the 



















Both individuals and behaviors 
are associated with normative 
and attitudinal control. 
Combined for 85%health 
intention variance. 
Closer examination of social 
influences to address the weak 
association between subjective 
norm and intention. 





Title Theory Type of Study/ 
Unit of Analysis 
Focus Critical Findings 
Millstein, 
1996 
Utility of the theories 
of reasoned action and 


















patients about the 
transmission of 




Studies in the past have found 
attitudes to have the stronger 
association (not social norms) 
on behavioral intentions.  
Behavioral intentions were 
strongly associated with 
attitudes and social norms 
(strongest influence) towards 
the behavior – prescribing 
antibiotics.  
Perceived behavioral control 
had direct effects on behavior 
and interacting with social 
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